Publications

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation
Jachetti E., Caputo S., Mazzoleni S., Brambillasca C. S., Parigi S. M., Grioni M., Piras I. S., Restuccia U., Calcinotto A., Freschi M., Bachi A., Galli R., Bellone M.
Epiregulation of the SASP makes good neighbors
Desbats M. A., Zumerle S., Alimonti A.
Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas
Taverna P., Catapano C. V., Citti L., Bonfanti M., D'Incalci M.
Nuclear matrix targets for anticancer agents
Fernandes D. J., Catapano C. V.
Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate
Catapano C. V., Chandler K. B., Fernandes D. J.
Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients
Limonta M., Ubezio P., Catapano C. V., Conter V., Costato C., Masera G., Specchia G., Liso V., Barbui T., Giudici G., et al.
O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia
D'Incalci M., Taverna P., Erba E., Filippeschi S., Potenza D., Mariani L., Citti L., Catapano C. V.
Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells
Limonta M., Biondi A., Giudici G., Specchia G., Catapano C., Masera G., Barbui T., D'Incalci M.
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation
Zucchetti M., Catapano C. V., Filippeschi S., Erba E., D'Incalci M.
The relevance of DNA repair in the cytotoxic response of mammalian cells to alkylating agents
Citti L., Mariani L., Catapano C. V., Malvaldi G.
Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy
D'Incalci M., Citti L., Taverna P., Catapano C. V.
Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats
Catapano C. V., Guaitani A., Broggini M., Corada M., Bartosek I., Italia C., Donelli M. G.
Intracellular drug concentration and DNA damage in human childhood leukemic cells exposed to doxorubicin
Catapano C. V., Ubezio P., Rossi V., Conter V., Jancovich M., D'Incalci M.
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas
Catapano C. V., Broggini M., Erba E., Ponti M., Mariani L., Citti L., D'Incalci M.
DNA topoisomerase II isozymes involved in anticancer drug action and resistance
Fernandes D. J., Qiu J., Catapano C. V.
Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene
Lorico A., Rappa G., Srimatkandada S., Catapano C. V., Fernandes D. J., Germino J. F., Sartorelli A. C.
Primer RNA chain termination induced by 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate. A mechanism of DNA synthesis inhibition
Catapano C. V., Perrino F. W., Fernandes D. J.
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells
Limonta M., Colombo T., Damia G., Catapano C. V., Conter V., Gervasoni M., Masera G., Liso V., Specchia G., Giudici G., et al.
GTP depletion induced by IMP dehydrogenase inhibitors blocks RNA-primed DNA synthesis
Catapano C. V., Dayton J. S., Mitchell B. S., Fernandes D. J.
Effect of chronic infusion of cortisol on renin gene expression and renin response to hemorrhage in fetal lambs
Carbone G. M., Sheikh A. U., Zehnder T., Rose J. C.
Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26
Danks M. K., Qiu J., Catapano C. V., Schmidt C. A., Beck W. T., Fernandes D. J.
Expression of manganese superoxide dismutase in ovine kidney cortex during development
Carbone G. M., St Clair D. K., Xu Y. A., Rose J. C.
Developmental changes in renin gene expression in ovine kidney cortex
Carbone G. M., Sheikh A. U., Rogers S., Brewer G., Rose J. C.
The nuclear matrix as a site of anticancer drug action
Fernandes D. J., Catapano C. V.
The nuclear matrix as a target for cancer therapy
Catapano C. V., Carbone G. M., Fernandes D. J.
The nuclear matrix as a target for cancer therapy
Catapano C. V., Carbone G. M., Fernandes D. J.
Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity
Qiu J., Catapano C. V., Fernandes D. J.
Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas
Zucca E., Bertoni F., Bosshard G., Roggero E., Ceresa E., Sanna P., Pedrinis E., Cavalli F.
Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy
Foa P., Iurlo A., Orazi A., Saglio G., Ribera S., Bertoni F., Caldiera S., Fornier M., Maiolo A. T.
Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26
Catapano C. V., Carbone G. M., Pisani F., Qiu J., Fernandes D. J.
Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26
Catapano C. V., Carbone G. M., Pisani F., Qiu J., Fernandes D. J.
Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process
Bertoni F., Cazzaniga G., Bosshard G., Roggero E., Barbazza R., De Boni M., Capella C., Pedrinis E., Cavalli F., Biondi A., Zucca E.
Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas
Zucca E., Roggero E., Bertoni F., Cavalli F.
Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma
Pinotti G., Zucca E., Roggero E., Pascarella A., Bertoni F., Savio A., Savio E., Capella C., Pedrinis E., Saletti P., Morandi E., Santandrea G., Cavalli F.
Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?
Iurlo A., Fornier M., Caldiera S., Bertoni F., Foa P.
[Supradiaphragmatic right-sided space-occupying lesion]
Sanna P., Bertoni F., Zucca E., Sustar N., Bonillar J., Cavalli F., Kauzlaric D.
Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach
Zucca E., Bertoni F., Roggero E., Bosshard G., Cazzaniga G., Pedrinis E., Biondi A., Cavalli F.
Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach
Zucca E., Bertoni F., Roggero E., Cazzaniga G., Bosshard G., Biondi A., Cavalli F.
Primary extranodal lymphoma of skeletal muscles: a report of four cases
Bertoni F., Sanna P., Zucca E., Roggero E., Cavalli F.
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera
Foa P., Massaro P., Caldiera S., LaTargia M. L., Iurlo A., Clerici C., Fornier M., Bertoni F., Maiolo A. T.
Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa
Baldini L., Blini M., Guffanti A., Fossati V., Colombi M., La Targia M. L., Bertoni F., Alietti A., Neri A., Bertoni G.
Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature
Sanna P., Bertoni F., Zucca E., Roggero E., Passega Sidler E., Fiori G., Pedrinis E., Mombelli G., Cavalli F.
Management of rare forms of lymphoma
Zucca E., Bertoni F., Roggero E., Cavalli F.
Clonality assessment in blood of patients with mantle cell lymphoma
Bertoni F., Roggero E., Luscieti P., Pedrinis E., Cavalli F., Zucca E.
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity
Erba E., Bergamaschi D., Ronzoni S., Faretta M., Taverna S., Bonfanti M., Catapano C. V., Faircloth G., Jimeno J., D'Incalci M.
CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
Bertoni F., Codegoni A. M., Furlan D., Tibiletti M. G., Capella C., Broggini M.
Allelic expression of p73 in human ovarian cancers
Codegoni A. M., Bertoni F., Patregnani C., Marinetti E., D'Incalci M., Broggini M.
Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma
Bertoni F., Cotter F. E., Zucca E.
Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites
Zucca E., Roggero E., Bertoni F., Conconi A., Cavalli F.
Analysis of BCL-10 gene mutations in ovarian cancer cell lines
Bertoni F., Luminari S., Intini D., Carobbio S., Codegoni A. M., Spataro V., Neri A.
Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials
Bieri S., Roggero E., Zucca E., Bertoni F., Pianca S., Sanna P., Pedrinis E., Bernier J., Cavalli F.
Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma
Bertoni F., Zucca E., Genini D., Cazzaniga G., Roggero E., Ghielmini M., Cavalli F., Biondi A.
Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland
Zucca E., Roggero E., Maggi-Solcà N., Conconi A., Bertoni F., Reilly I., Castelli D., Pedrinis E., Piffaretti J. C., Cavalli F.
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M., Schmitz S. F., Bürki K., Pichert G., Betticher D. C., Stupp R., Wernli M., Lohri A., Schmitter D., Bertoni F., Cerny T.
Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas
Bertoni F., Conconi A., Luminari S., Realini C., Roggero E., Baldini L., Carobbio S., Cavalli F., Neri A., Zucca E.
Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer
Codegoni A. M., Bertoni F., Colella G., Caspani G., Grassi L., D'Incalci M., Broggini M.
Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines
Bertoni F., Conconi A., Carobbio S., Realini C., Codegoni A. M., Zucca E., Cavalli F.
Association of gastric and Waldeyer's ring lymphoma: a molecular study
Bertoni F., Sanna P., Tinguely M., Roggero E., Conconi A., Gisi M., Cazzaniga G., Biondi A., Pedrinis E., Cavalli F., Zucca E.
BCL10 gene mutations rarely occur in lymphoid malignancies
Luminari S., Intini D., Baldini L., Berti E., Bertoni F., Zucca E., Cro L., Maiolo A. T., Cavalli F., Neri A.
Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene
Catapano C. V., McGuffie E. M., Pacheco D., Carbone G. M.
Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene
Catapano C. V., McGuffie E. M., Pacheco D., Carbone G. M.
The gastric marginal zone B-cell lymphoma of MALT type
Zucca E., Bertoni F., Roggero E., Cavalli F.
Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma
Carbone A., Cilia A. M., Gloghini A., Capello D., Fassone L., Perin T., Rossi D., Canzonieri V., De Paoli P., Vaccher E., Tirelli U., Volpe R., Gaidano G.
Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma
Carbone A., Cilia A. M., Gloghini A., Capello D., Fassone L., Perin T., Rossi D., Canzonieri V., De Paoli P., Vaccher E., Tirelli U., Volpe R., Gaidano G.
Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells
McGuffie E. M., Pacheco D., Carbone G. M., Catapano C. V.
Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells
McGuffie E. M., Pacheco D., Carbone G. M., Catapano C. V.
Common-variable immunodeficiency-related lymphomas associate with mutations and rearrangements of BCL-6: pathogenetic and histogenetic implications
Ariatti C., Vivenza D., Capello D., Migliazza A., Parvis G., Fassone L., Buonaiuto D., Savinelli F., Rossi D., Saglio G., Gaidano G.
Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reaction
Bertoni F., Müllenbach R., Broggini M., Roggero E., Cavalli F., Cotter F. E., Zucca E.
Prognostic models for diffuse large B-cell lymphoma
Conconi A., Zucca E., Roggero E., Bertoni F., Bernasconi A., Mingrone W., Pedrinis E., Cavalli F.
Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma
Bertoni F., Gisi M., Roggero E., Conconi A., Mingrone W., Cavalli F., Zucca E.
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells
Carbone G. M., Catapano C. V., Fernandes D. J.
Imbalanced DNA synthesis induced by cytosine arabinoside and fludarabine in human leukemia cells
Carbone G. M., Catapano C. V., Fernandes D. J.
Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes
Conconi A., Bertoni F., Pedrinis E., Motta T., Roggero E., Luminari S., Capella C., Bonato M., Cavalli F., Zucca E.
Synergistic interaction between topotecan and microtubule-interfering agents
Bahadori H. R., Green M. R., Catapano C. V.
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma
Esteller M., Gaidano G., Goodman S. N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S. B., Herman J. G.
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma
Esteller M., Gaidano G., Goodman S. N., Zagonel V., Capello D., Botto B., Rossi D., Gloghini A., Vitolo U., Carbone A., Baylin S. B., Herman J. G.
Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial
Bertoni F., Conconi A., Capella C., Motta T., Giardini R., Ponzoni M., Pedrinis E., Novero D., Rinaldi P., Cazzaniga G., Biondi A., Wotherspoon A., Hancock B. W., Smith P., Souhami R., Cotter F. E., Cavalli F., Zucca E.
Genetic alterations underlying the pathogenesis of MALT lymphoma
Bertoni F., Cavalli F., Cotter F. E., Zucca E.
Human herpesvirus type 8-associated primary lymphomatous effusion in an elderly HIV-negative patient: clinical and molecular characterization
Buonaiuto D., Rossi D., Guidetti F., Vivenza D., Berra E., Deambrogi C., Ariatti C., Franceschetti S., Conconi A., Ronco M., Valente G., Colombi S.
Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene
McGuffie E. M., Catapano C. V.
The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23
Auer R. L., Bertoni F., Jones C., Cotter F. E.
Alternative translocation breakpoint cluster region 5' to BCL-6 in B-cell non-Hodgkin's lymphoma
Butler M. P., Iida S., Capello D., Rossi D., Rao P. H., Nallasivam P., Louie D. C., Chaganti S., Au T., Gascoyne R. D., Gaidano G., Chaganti R. S., Dalla-Favera R.
Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity
Paulli M., Viglio A., Vivenza D., Capello D., Rossi D., Riboni R., Lucioni M., Incardona P., Boveri E., Bellosta M., Orlandi E., Borroni G., Lazzarino M., Berti E., Alessi E., Magrini U., Gaidano G.
Anaplastic large cell lymphoma and acquired angioedema: a novel association?
Rossi D., Gaidano G.
Mantle cell lymphoma: new treatments targeted to the biology
Bertoni F., Ghielmini M., Cavalli F., Cotter F. E., Zucca E.
Molecular histogenesis of plasmablastic lymphoma of the oral cavity
Gaidano G., Cerri M., Capello D., Berra E., Deambrogi C., Rossi D., Larocca L. M., Campo E., Gloghini A., Tirelli U., Carbone A.
Molecular histogenesis of plasmablastic lymphoma of the oral cavity
Gaidano G., Cerri M., Capello D., Berra E., Deambrogi C., Rossi D., Larocca L. M., Campo E., Gloghini A., Tirelli U., Carbone A.
Simian virus 40 infection in lymphoproliferative disorders
Capello D., Rossi D., Gaudino G., Carbone A., Gaidano G.
Simian virus 40 infection in lymphoproliferative disorders
Capello D., Rossi D., Gaudino G., Carbone A., Gaidano G.
Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia
Fu W. N., Bertoni F., Kelsey S. M., McElwaine S. M., Cotter F. E., Newland A. C., Jia L.
Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide
Carbone G. M., McGuffie E. M., Collier A., Catapano C. V.
Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide
Carbone G. M., McGuffie E. M., Collier A., Catapano C. V.
Messengers of cell death: apoptotic signaling in health and disease
Rossi D., Gaidano G.
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer
Alimonti A., Satta F., Pavese I., Burattini E., Zoffoli V., Vecchione A.
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma
Gaidano G., Pasqualucci L., Capello D., Berra E., Deambrogi C., Rossi D., Maria Larocca L., Gloghini A., Carbone A., Dalla-Favera R.
Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma
Gaidano G., Pasqualucci L., Capello D., Berra E., Deambrogi C., Rossi D., Maria Larocca L., Gloghini A., Carbone A., Dalla-Favera R.
A new mathematical model based on clinical and laboratory variables for the diagnosis of Sjögren's syndrome
Martin-Martin L. S., Latini A., Pagano A., Ragno A., Stasi R., Coppè A., Davoli G., Crescenzi A., Alimonti A., Migliore A.
Subacute motor weakness and left renal mass
Alimonti A., Di Cosimo S., Di Stani F., Vecchione A., Di Palma M., Ferretti G.
Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target
Remsing L. L., Bahadori H. R., Carbone G. M., McGuffie E. M., Catapano C. V., Rohr J.
Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target
Remsing L. L., Bahadori H. R., Carbone G. M., McGuffie E. M., Catapano C. V., Rohr J.
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide
Bacci G., Briccoli A., Rocca M., Ferrari S., Donati D., Longhi A., Bertoni F., Bacchini P., Giacomini S., Forni C., Manfrini M., Galletti S.
Molecular histogenesis of posttransplantation lymphoproliferative disorders
Capello D., Cerri M., Muti G., Berra E., Oreste P., Deambrogi C., Rossi D., Dotti G., Conconi A., Viganò M., Magrini U., Ippoliti G., Morra E., Gloghini A., Rambaldi A., Paulli M., Carbone A., Gaidano G.
Molecular histogenesis of posttransplantation lymphoproliferative disorders
Capello D., Cerri M., Muti G., Berra E., Oreste P., Deambrogi C., Rossi D., Dotti G., Conconi A., Viganò M., Magrini U., Ippoliti G., Morra E., Gloghini A., Rambaldi A., Paulli M., Carbone A., Gaidano G.
Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma
Zucca E., Bertoni F., Cavalli F.
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
Alimonti A., Ferretti G., Di Cosimo S., Cognetti F., Vecchione A.
Long-term follow-up in breast cancer survivors: a single institution survey
Di Cosimo S., Ferretti G., Alimonti A., Gravante G., Silvestris N., D'Aprile M.
Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases
Favier R., Jondeau K., Boutard P., Grossfeld P., Reinert P., Jones C., Bertoni F., Cramer E. M.
Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas
Rossi D., Gaidano G., Gloghini A., Deambrogi C., Franceschetti S., Berra E., Cerri M., Vendramin C., Conconi A., Viglio A., Muti G., Oreste P., Morra E., Paulli M., Capello D., Carbone A.
Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas
Rossi D., Gaidano G., Gloghini A., Deambrogi C., Franceschetti S., Berra E., Cerri M., Vendramin C., Conconi A., Viglio A., Muti G., Oreste P., Morra E., Paulli M., Capello D., Carbone A.
Molecular basis of mantle cell lymphoma
Bertoni F., Zucca E., Cotter F. E.
Docetaxel in advanced gastric cancer--review of the main clinical trials
Di Cosimo S., Ferretti G., Fazio N., Silvestris N., Carlini P., Alimonti A., Gelibter A., Felici A., Papaldo P., Cognetti F.
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Bertoni F., Conconi A., Cogliatti S. B., Schmitz S. F., Ghielmini M., Cerny T., Fey M., Pichert G., Bertolini F., Ponzoni M., Baldini L., Jones C., Auer R., Zucca E., Cavalli F., Cotter F. E.
HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
Ferretti G., Di Cosimo S., Giannarelli D., Carlini P., Papaldo P., Alimonti A., Fabi A., Mandalà M., Milella M., Ruggeri E. M., Cognetti F.
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency
Forconi F., Capello D., Berra E., Rossi D., Gloghini A., Cerri M., Muti G., Morra E., Paulli M., Magrini U., Lucioni M., Rambaldi A., Lauria F., Carbone A., Stevenson F. K., Gaidano G.
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency
Forconi F., Capello D., Berra E., Rossi D., Gloghini A., Cerri M., Muti G., Morra E., Paulli M., Magrini U., Lucioni M., Rambaldi A., Lauria F., Carbone A., Stevenson F. K., Gaidano G.
CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells
Corcione A., Arduino N., Ferretti E., Raffaghello L., Roncella S., Rossi D., Fedeli F., Ottonello L., Trentin L., Dallegri F., Semenzato G., Pistoia V.
Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis
Rossi D., Gaidano G.
Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia
Rossi D., Capello D., Gloghini A., Franceschetti S., Paulli M., Bhatia K., Saglio G., Vitolo U., Pileri S. A., Esteller M., Carbone A., Gaidano G.
Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia
Rossi D., Capello D., Gloghini A., Franceschetti S., Paulli M., Bhatia K., Saglio G., Vitolo U., Pileri S. A., Esteller M., Carbone A., Gaidano G.
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors
Rocha Lima C. M., Catapano C. V., Pacheco D., Sherman C. A., Oakhill G., Mushtaq C., Freeman K. D., Green M. R.
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer
Di Cosimo S., Alimonti A., Ferretti G., Sperduti I., Carlini P., Papaldo P., Fabi A., Gelibter A., Ciccarese M., Giannarelli D., Mandalà M., Milella M., Ruggeri E. M., Cognetti F.
Is video-assisted thoracic surgery always safe?
Alimonti A., Di Cosimo S., Di Palma M., Ferretti G., Vecchione A.
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)]
Di Cosimo S., Ferretti G., Milella M., Martinelli E., Alimonti A., Papaldo P., Carlini P., Fabi A., Matar P., Cognetti F.
[Safety profile of 185 ultrasound-guided intra-articular injections for treatment of rheumatic diseases of the hip]
Migliore A., Tormenta S., Martin Martin L. S., Valente C., Massafra U., Latini A., Alimonti A.
New approaches to prevent intestinal toxicity of irinotecan-based regimens
Alimonti A., Gelibter A., Pavese I., Satta F., Cognetti F., Ferretti G., Rasio D., Vecchione A., Di Palma M.
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas
Ferreri A. J., Dell'Oro S., Capello D., Ponzoni M., Iuzzolino P., Rossi D., Pasini F., Ambrosetti A., Orvieto E., Ferrarese F., Arrigoni G., Foppoli M., Reni M., Gaidano G.
Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders
Cerri M., Capello D., Muti G., Rambaldi A., Paulli M., Gloghini A., Berra E., Deambrogi C., Rossi D., Franceschetti S., Conconi A., Morra E., Pasqualucci L., Carbone A., Gaidano G.
Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders
Cerri M., Capello D., Muti G., Rambaldi A., Paulli M., Gloghini A., Berra E., Deambrogi C., Rossi D., Franceschetti S., Conconi A., Morra E., Pasqualucci L., Carbone A., Gaidano G.
Mantle cell lymphoma
Bertoni F., Zucca E., Cavalli F.
Open pilot study of ultrasound-guided intra-articular injection of hylan G-F 20 (Synvisc) in the treatment of symptomatic hip osteoarthritis
Migliore A., Tormenta S., Martin L. S., Valente C., Massafra U., Granata M., Alimonti A.
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M., Schmitz S. F., Cogliatti S., Bertoni F., Waltzer U., Fey M. F., Betticher D. C., Schefer H., Pichert G., Stahel R., Ketterer N., Bargetzi M., Cerny T.
Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy
Martinelli G., Laszlo D., Ferreri A. J., Pruneri G., Ponzoni M., Conconi A., Crosta C., Pedrinis E., Bertoni F., Calabrese L., Zucca E.
Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia
Auer R. L., Starczynski J., McElwaine S., Bertoni F., Newland A. C., Fegan C. D., Cotter F. E.
POEMS and calciphylaxis: a novel association?
Rossi D., Gaidano G.
[Intra-articular treatment with Hylan G-F 20 under ultrasound guidance in hip osteoarthritis. Clinical results after 12 months follow-up]
Migliore A., Tormenta S., Valente C., Massafra U., Martin Martin L. S., Carmenini E., Bernardini A., Alimonti A.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Lacrima K., Valentini A., Lambertini C., Taborelli M., Rinaldi A., Zucca E., Catapano C., Cavalli F., Gianella-Borradori A., Maccallum D. E., Bertoni F.
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas
Lacrima K., Valentini A., Lambertini C., Taborelli M., Rinaldi A., Zucca E., Catapano C., Cavalli F., Gianella-Borradori A., Maccallum D. E., Bertoni F.
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Di Cosimo S., Ferretti G., Papaldo P., Carlini P., Fabi A., Ruggeri E. M., Alimonti A., Nardoni C., Cognetti F.
IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome
Cogliatti S. B., Bertoni F., Zimmermann D. R., Henz S., Diss T. C., Ghielmini M., Schmid U.
Another Piece of the MALT Lymphomas Jigsaw
Zucca E., Bertoni F.
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells
Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A.
Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development
Sirianni M. C., Libi F., Campagna M., Rossi D., Capello D., Sciaranghella G., Carbone A., Simonelli C., Monini P., Gaidano G., Ensoli B.
Downregulation of the major histocompatibility complex class I molecules by human herpesvirus type 8 and impaired natural killer cell activity in primary effusion lymphoma development
Sirianni M. C., Libi F., Campagna M., Rossi D., Capello D., Sciaranghella G., Carbone A., Simonelli C., Monini P., Gaidano G., Ensoli B.
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients
Ferretti G., Fabi A., Carlini P., Papaldo P., Cordiali Fei P., Di Cosimo S., Salesi N., Giannarelli D., Alimonti A., Di Cocco B., D'Agosto G., Bordignon V., Trento E., Cognetti F.
Nail disorders in a woman treated with ixabepilone for metastatic breast cancer
Alimonti A., Nardoni C., Papaldo P., Ferretti G., Caleno M. P., Carlini P., Fabi A., Rasio D., Vecchione A., Cognetti F.
State-of-the-art therapeutics: marginal-zone lymphoma
Bertoni F., Zucca E.
Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis
Capello D., Rossi D., Gaidano G.
Repeated ultrasound-guided intra-articular injections of 40 mg of Hyalgan may be useful in symptomatic relief of hip osteoarthritis
Migliore A., Tormenta S., Massafra U., Carloni E., Padalino C., Iannessi F., Alimonti A., Martin L. S., Granata M.
The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up
Migliore A., Tormenta S., Martin Martin L. S., Iannessi F., Massafra U., Carloni E., Monno D., Alimonti A., Granata M.
Can the reliance of hormone receptor assays of surgical specimens be explained by the fluctuation of estrogen receptor, progesterone receptor, and HER-2 protein expression in tumor samples of premenopausal breast cancer patients?
Alimonti A., Ferretti G., Cognetti F.
Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets
Chtanova T., Newton R., Liu S. M., Weininger L., Young T. R., Silva D. G., Bertoni F., Rinaldi A., Chappaz S., Sallusto F., Rolph M. S., Mackay C. R.
Delving deeper into MALT lymphoma biology
Bertoni F., Zucca E.
Update on the molecular biology of mantle cell lymphoma
Bertoni F., Rinaldi A., Zucca E., Cavalli F.
TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: a seven cases report
Migliore A., Massafra U., Carloni E., Padalino C., Martin Martin S., Lasaracina F., Dibiase N., Alimonti A., Granata M.
Chromosome band 6q deletion pattern in malignant lymphomas
Taborelli M., Tibiletti M. G., Martin V., Pozzi B., Bertoni F., Capella C.
Usefulness of JAK2V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera
Rossi D., Cortini F., Deambrogi C., Barbieri C., Cerri M., Franceschetti S., Conconi A., Capello D., Gaidano G.
[18-month observational study on efficacy of intraarticular hyaluronic acid (Hylan G-F 20) injections under ultrasound guidance in hip osteoarthritis]
Migliore A., Tormenta S., Massafra U., Martin Martin L. S., Carloni E., Padalino C., Alimonti A., Granata M.
Identification of a tumour suppressor network opposing nuclear Akt function
Trotman L. C., Alimonti A., Scaglioni P. P., Koutcher J. A., Cordon-Cardo C., Pandolfi P. P.
A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression
Macagno A., Molteni M., Rinaldi A., Bertoni F., Lanzavecchia A., Rossetti C., Sallusto F.
Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas
Rinaldi A., Kwee I., Poretti G., Mensah A., Pruneri G., Capello D., Rossi D., Zucca E., Ponzoni M., Catapano C., Tibiletti M. G., Paulli M., Gaidano G., Bertoni F.
Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas
Rinaldi A., Kwee I., Poretti G., Mensah A., Pruneri G., Capello D., Rossi D., Zucca E., Ponzoni M., Catapano C., Tibiletti M. G., Paulli M., Gaidano G., Bertoni F.
Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas
Rinaldi A., Kwee I., Poretti G., Mensah A., Pruneri G., Capello D., Rossi D., Zucca E., Ponzoni M., Catapano C., Tibiletti M. G., Paulli M., Gaidano G., Bertoni F.
Synthesis and anticancer activity of cyclopalladated complexes containing 4-hydroxy-acridine
Pucci D., Albertini V., Bloise R., Bellusci A., Cataldi A., Catapano C. V., Ghedini M., Crispini A.
Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders
Capello D., Cerri M., Muti G., Lucioni M., Oreste P., Gloghini A., Berra E., Deambrogi C., Franceschetti S., Rossi D., Alabiso O., Morra E., Rambaldi A., Carbone A., Paulli M., Gaidano G.
Analysis of immunoglobulin heavy and light chain variable genes in post-transplant lymphoproliferative disorders
Capello D., Cerri M., Muti G., Lucioni M., Oreste P., Gloghini A., Berra E., Deambrogi C., Franceschetti S., Rossi D., Alabiso O., Morra E., Rambaldi A., Carbone A., Paulli M., Gaidano G.
PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
Bernardi R., Guernah I., Jin D., Grisendi S., Alimonti A., Teruya-Feldstein J., Cordon-Cardo C., Simon M. C., Rafii S., Pandolfi P. P.
JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders
Rossi D., Deambrogi C., Capello D., Cerri M., Lunghi M., Parvis G., Saglio G., Gaidano G., Cilloni D.
Determination of Cd, Cu, Pb and Zn in neoplastic kidneys and in renal tissue of fetuses, newborns and corpses
Cerulli N., Campanella L., Grossi R., Politi L., Scandurra R., Soda G., Gallo F., Damiani S., Alimonti A., Petrucci F., Caroli S.
Hairy cell leukaemia complicated by anti-MAG paraproteinemic demyelinating neuropathy: resolution of neurological syndrome after cladribrine treatment
Rossi D., Franceschetti S., Cerri M., Conconi A., Lunghi M., Capello D., Cantello R., Gaidano G.
Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma
Rossi D., Berra E., Cerri M., Deambrogi C., Barbieri C., Franceschetti S., Lunghi M., Conconi A., Paulli M., Matolcsy A., Pasqualucci L., Capello D., Gaidano G.
Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa?
Zucca E., Bertoni F.
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G. M., Catapano C. V.
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G. M., Catapano C. V.
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G. M., Catapano C. V.
Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
Vignati S., Albertini V., Rinaldi A., Kwee I., Riva C., Oldrini R., Capella C., Bertoni F., Carbone G. M., Catapano C. V.
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
Ferretti G., Alimonti A., Cognetti F.
B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution
Lucioni M., Capello D., Riboni R., Ippoliti G., Campana C., Bandiera L., Arcaini L., Rossi D., Cerri M., Dionigi P., Lazzarino M., Magrini U., Viganò M., Gaidano G., Paulli M.
Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease
Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L., Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D., Lambertenghi-Deliliers G., Bertoni F., Neri A.
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN
Wang X., Trotman L. C., Koppie T., Alimonti A., Chen Z., Gao Z., Wang J., Erdjument-Bromage H., Tempst P., Cordon-Cardo C., Pandolfi P. P., Jiang X.
Ubiquitination regulates PTEN nuclear import and tumor suppression
Trotman L. C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., Pavletich N. P., Carver B. S., Cordon-Cardo C., Erdjument-Bromage H., Tempst P., Chi S. G., Kim H. J., Misteli T., Jiang X., Pandolfi P. P.
Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma
Agnelli L., Bicciato S., Fabris S., Baldini L., Morabito F., Intini D., Verdelli D., Callegaro A., Bertoni F., Lambertenghi-Deliliers G., Lombardi L., Neri A.
Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases
Campidelli C., Sabattini E., Piccioli M., Rossi M., De Blasi D., Miraglia E., Rodriguez-Abreu D., Franscini L. L., Bertoni F., Mazzucchelli L., Cavalli F., Zucca E., Pileri S. A.
Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients
Gracia E., Froesch P., Mazzucchelli L., Martin V., Rodríguez-Abreu D., Jiménez J., Melgares M., Santos D., Capó V., Cavalli F., Zucca E., Bertoni F.
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
Griggio V., Vitale C., Todaro M., Riganti C., Kopecka J., Salvetti C., Bomben R., Bo M. D., Magliulo D., Rossi D., Pozzato G., Bonello L., Marchetti M., Omedè P., Kodipad A. A., Laurenti L., Del Poeta G., Mauro F. R., Bernardi R., Zenz T., Gattei V., Gaidano G., Foà R., Massaia M., Boccadoro M., Coscia M.
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
Rinaldi A., Poretti G., Kwee I., Zucca E., Catapano C. V., Tibiletti M. G., Bertoni F.
Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma
Rinaldi A., Poretti G., Kwee I., Zucca E., Catapano C. V., Tibiletti M. G., Bertoni F.
[Correlation between radiologic and ultrasonographic patterns and clinical manifestations in symptomatic hip osteoarthritis]
Migliore A., Tormenta S., Iannessi F., Mascheroni E., Barbati E., Capuano A., Diaco M., Massafra U., Padalino C., Vacca F., Alimonti A., Martin L. S., Granata M.
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients
Carlini P., Michelotti A., Ferretti G., Ricci S., Giannarelli D., Pellegrini M., Cresti N., Di Cosimo S., Bria E., Papaldo P., Fabi A., Ruggeri E. M., Milella M., Alimonti A., Salesi N., Cognetti F.
Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance
Rossi D., De Paoli L., Franceschetti S., Capello D., Vendramin C., Lunghi M., Conconi A., Magnani C., Gaidano G.
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
Ponzoni M., Berger F., Chassagne-Clement C., Tinguely M., Jouvet A., Ferreri A. J., Dell'Oro S., Terreni M. R., Doglioni C., Weis J., Cerati M., Milani M., Iuzzolino P., Motta T., Carbone A., Pedrinis E., Sanchez J., Blay J. Y., Reni M., Conconi A., Bertoni F., Zucca E., Cavalli F., Borisch B.
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas
Ponzoni M., Berger F., Chassagne-Clement C., Tinguely M., Jouvet A., Ferreri A. J., Dell'Oro S., Terreni M. R., Doglioni C., Weis J., Cerati M., Milani M., Iuzzolino P., Motta T., Carbone A., Pedrinis E., Sanchez J., Blay J. Y., Reni M., Conconi A., Bertoni F., Zucca E., Cavalli F., Borisch B.
The cellular origin of mantle cell lymphoma
Bertoni F., Ponzoni M.
Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type
Tibiletti M. G., Milani K., Martin V., Zucca E., Motta T., Cortelazzo S., Pinotti G., Mazzucchelli L., Pruneri G., Martinelli G., Barbazza R., Capella C., Bertoni F.
Bendamustine in lymphomas: more to combine?
Bertoni F., Zucca E.
Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection
Rossi D., Franceschetti S., Capello D., De Paoli L., Lunghi M., Conconi A., Gaidano G.
JAK2V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia
Rossi D., Cresta S., Destro T., Vendramin C., Bocchetta S., De Paoli L., Cerri M., Lunghi M., Gaidano G.
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals
Ponzoni M., Kwee I., Mazzucchelli L., Ferreri A. J., Zucca E., Doglioni C., Cavalli F., Bertoni F.
Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma
Fabris S., Todoerti K., Mosca L., Agnelli L., Intini D., Lionetti M., Guerneri S., Lambertenghi-Deliliers G., Bertoni F., Neri A.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ferreri A. J., Dolcetti R., Du M. Q., Doglioni C., Resti A. G., Politi L. S., De Conciliis C., Radford J., Bertoni F., Zucca E., Cavalli F., Ponzoni M.
Bone marrow necrosis complicating post-transplant lymphoproliferative disorder: resolution with rituximab
Rossi D., Ramponi A., Franceschetti S., Stratta P., Gaidano G.
The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells
Lozza L., Rivino L., Guarda G., Jarrossay D., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A., Geginat J.
Oncogenic BARD1 isoforms expressed in gynecological cancers
Li L., Ryser S., Dizin E., Pils D., Krainer M., Jefford C. E., Bertoni F., Zeillinger R., Irminger-Finger I.
Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia
Rossi D., Rasi S., Capello D., Gaidano G.
Hematological Oncology: further ahead
Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis
Pruneri G., Alietti A., Agnelli L., Morabito F., Laszlo D., Calabrese L., Fabris S., Bertolini F., Agazzi A., Bottiglieri L., Raviele P. R., Baldini L., Pileri S., Sabattini E., Bosari S., Maisonneuve P., Lambertenghi-Deliliers G., Bertoni F., Martinelli G., Viale G., Neri A.
Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice
Migliore A., Tormenta S., Massafra U., Bizzi E., Iannessi F., Alimonti A., Granata M.
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia
Forconi F., Poretti G., Kwee I., Sozzi E., Rossi D., Rancoita P. M., Capello D., Rinaldi A., Zucca E., Raspadori D., Spina V., Lauria F., Gaidano G., Bertoni F.
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia
Forconi F., Poretti G., Kwee I., Sozzi E., Rossi D., Rancoita P. M., Capello D., Rinaldi A., Zucca E., Raspadori D., Spina V., Lauria F., Gaidano G., Bertoni F.
Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas
Furlan D., Sahnane N., Carnevali I., Cerutti R., Bertoni F., Kwee I., Uccella S., Bertolini V., Chiaravalli A. M., Capella C.
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
Cresta S., Sessa C., Catapano C. V., Gallerani E., Passalacqua D., Rinaldi A., Bertoni F., Viganò L., Maur M., Capri G., Maccioni E., Tosi D., Gianni L.
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours
Cresta S., Sessa C., Catapano C. V., Gallerani E., Passalacqua D., Rinaldi A., Bertoni F., Viganò L., Maur M., Capri G., Maccioni E., Tosi D., Gianni L.
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events
Nardella C., Chen Z., Salmena L., Carracedo A., Alimonti A., Egia A., Carver B., Gerald W., Cordon-Cardo C., Pandolfi P. P.
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A. T., Thomas G., Kozma S. C., Papa A., Nardella C., Cantley L. C., Baselga J., Pandolfi P. P.
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
Forconi F., Rinaldi A., Kwee I., Sozzi E., Raspadori D., Rancoita P. M., Scandurra M., Rossi D., Deambrogi C., Capello D., Zucca E., Marconi D., Bomben R., Gattei V., Lauria F., Gaidano G., Bertoni F.
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion
Forconi F., Rinaldi A., Kwee I., Sozzi E., Raspadori D., Rancoita P. M., Scandurra M., Rossi D., Deambrogi C., Capello D., Zucca E., Marconi D., Bomben R., Gattei V., Lauria F., Gaidano G., Bertoni F.
14q32 Translocations and risk of Richter transformation in chronic lymphocytic leukaemia
Deambrogi C., Cresta S., Cerri M., Rasi S., De Paoli L., Ramponi A., Gaidano G., Rossi D.
Marginal zone lymphomas
Zucca E., Bertoni F., Stathis A., Cavalli F.
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
Bomben R., Dal Bo M., Capello D., Forconi F., Maffei R., Laurenti L., Rossi D., Del Principe M. I., Zucchetto A., Bertoni F., Rossi F. M., Bulian P., Cattarossi I., Ilariucci F., Sozzi E., Spina V., Zucca E., Degan M., Lauria F., Del Poeta G., Efremov D. G., Marasca R., Gaidano G., Gattei V.
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
Bomben R., Dal Bo M., Capello D., Forconi F., Maffei R., Laurenti L., Rossi D., Del Principe M. I., Zucchetto A., Bertoni F., Rossi F. M., Bulian P., Cattarossi I., Ilariucci F., Sozzi E., Spina V., Zucca E., Degan M., Lauria F., Del Poeta G., Efremov D. G., Marasca R., Gaidano G., Gattei V.
Bayesian DNA copy number analysis
Rancoita P. M., Hutter M., Bertoni F., Kwee I.
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome
Tibiletti M. G., Martin V., Bernasconi B., Del Curto B., Pecciarini L., Uccella S., Pruneri G., Ponzoni M., Mazzucchelli L., Martinelli G., Ferreri A. J., Pinotti G., Assanelli A., Scandurra M., Doglioni C., Zucca E., Capella C., Bertoni F.
Differential requirement of mTOR in postmitotic tissues and tumorigenesis
Nardella C., Carracedo A., Alimonti A., Hobbs R. M., Clohessy J. G., Chen Z., Egia A., Fornari A., Fiorentino M., Loda M., Kozma S. C., Thomas G., Cordon-Cardo C., Pandolfi P. P.
Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
Stathis A., Chini C., Bertoni F., Proserpio I., Capella C., Mazzucchelli L., Pedrinis E., Cavalli F., Pinotti G., Zucca E.
ETS rearrangements and prostate cancer initiation
Carver B. S., Tran J., Chen Z., Carracedo-Perez A., Alimonti A., Nardella C., Gopalan A., Scardino P. T., Cordon-Cardo C., Gerald W., Pandolfi P. P.
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
Novak U., Rinaldi A., Kwee I., Nandula S. V., Rancoita P. M., Compagno M., Cerri M., Rossi D., Murty V. V., Zucca E., Gaidano G., Dalla-Favera R., Pasqualucci L., Bhagat G., Bertoni F.
The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
Novak U., Rinaldi A., Kwee I., Nandula S. V., Rancoita P. M., Compagno M., Cerri M., Rossi D., Murty V. V., Zucca E., Gaidano G., Dalla-Favera R., Pasqualucci L., Bhagat G., Bertoni F.
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03
Hitz F., Martinelli G., Zucca E., von Moos R., Mingrone W., Simcock M., Peterson J., Cogliatti S. B., Bertoni F., Zimmermann D. R., Ghielmini M.
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate
Carver B. S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P. T., Cordon-Cardo C., Gerald W., Pandolfi P. P.
A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect
Agnelli L., Mosca L., Fabris S., Lionetti M., Andronache A., Kwee I., Todoerti K., Verdelli D., Battaglia C., Bertoni F., Deliliers G. L., Neri A.
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma
Compagno M., Lim W. K., Grunn A., Nandula S. V., Brahmachary M., Shen Q., Bertoni F., Ponzoni M., Scandurra M., Califano A., Bhagat G., Chadburn A., Dalla-Favera R., Pasqualucci L.
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
Rossi D., Sozzi E., Puma A., De Paoli L., Rasi S., Spina V., Gozzetti A., Tassi M., Cencini E., Raspadori D., Pinto V., Bertoni F., Gattei V., Lauria F., Gaidano G., Forconi F.
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
Rossi D., Sozzi E., Puma A., De Paoli L., Rasi S., Spina V., Gozzetti A., Tassi M., Cencini E., Raspadori D., Pinto V., Bertoni F., Gattei V., Lauria F., Gaidano G., Forconi F.
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
Rossi D., Rasi S., Franceschetti S., Capello D., Castelli A., De Paoli L., Ramponi A., Chiappella A., Pogliani E. M., Vitolo U., Kwee I., Bertoni F., Conconi A., Gaidano G.
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
Rossi D., Rasi S., Franceschetti S., Capello D., Castelli A., De Paoli L., Ramponi A., Chiappella A., Pogliani E. M., Vitolo U., Kwee I., Bertoni F., Conconi A., Gaidano G.
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome
Rossi D., Spina V., Cerri M., Rasi S., Deambrogi C., De Paoli L., Laurenti L., Maffei R., Forconi F., Bertoni F., Zucca E., Agostinelli C., Cabras A., Lucioni M., Martini M., Magni M., Deaglio S., Ladetto M., Nomdedeu J. F., Besson C., Ramponi A., Canzonieri V., Paulli M., Marasca R., Larocca L. M., Carbone A., Pileri S. A., Gattei V., Gaidano G.
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome
Rossi D., Spina V., Cerri M., Rasi S., Deambrogi C., De Paoli L., Laurenti L., Maffei R., Forconi F., Bertoni F., Zucca E., Agostinelli C., Cabras A., Lucioni M., Martini M., Magni M., Deaglio S., Ladetto M., Nomdedeu J. F., Besson C., Ramponi A., Canzonieri V., Paulli M., Marasca R., Larocca L. M., Carbone A., Pileri S. A., Gattei V., Gaidano G.
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome
Rossi D., Spina V., Cerri M., Rasi S., Deambrogi C., De Paoli L., Laurenti L., Maffei R., Forconi F., Bertoni F., Zucca E., Agostinelli C., Cabras A., Lucioni M., Martini M., Magni M., Deaglio S., Ladetto M., Nomdedeu J. F., Besson C., Ramponi A., Canzonieri V., Paulli M., Marasca R., Larocca L. M., Carbone A., Pileri S. A., Gattei V., Gaidano G.
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior
Forconi F., Sozzi E., Cencini E., Zaja F., Intermesoli T., Stelitano C., Rigacci L., Gherlinzoni F., Cantaffa R., Baraldi A., Gallamini A., Zaccaria A., Pulsoni A., Gobbi M., Tassi M., Raspadori D., Leoncini L., Rinaldi A., Sabattini E., Bertoni F., Pileri S. A., Lauria F.
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis
Chen Z., Carracedo A., Lin H. K., Koutcher J. A., Behrendt N., Egia A., Alimonti A., Carver B. S., Gerald W., Teruya-Feldstein J., Loda M., Pandolfi P. P.
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
Dal-Bo M., Bertoni F., Forconi F., Zucchetto A., Bomben R., Marasca R., Deaglio S., Laurenti L., Efremov D. G., Gaidano G., Del Poeta G., Gattei V.
Genome wide DNA-profiling of HIV-related B-cell lymphomas
Capello D., Scandurra M., Poretti G., Rancoita P. M., Mian M., Gloghini A., Deambrogi C., Martini M., Rossi D., Greiner T. C., Chan W. C., Ponzoni M., Moreno S. M., Piris M. A., Canzonieri V., Spina M., Tirelli U., Inghirami G., Rinaldi A., Zucca E., Favera R. D., Cavalli F., Larocca L. M., Kwee I., Carbone A., Gaidano G., Bertoni F.
Genome wide DNA-profiling of HIV-related B-cell lymphomas
Capello D., Scandurra M., Poretti G., Rancoita P. M., Mian M., Gloghini A., Deambrogi C., Martini M., Rossi D., Greiner T. C., Chan W. C., Ponzoni M., Moreno S. M., Piris M. A., Canzonieri V., Spina M., Tirelli U., Inghirami G., Rinaldi A., Zucca E., Favera R. D., Cavalli F., Larocca L. M., Kwee I., Carbone A., Gaidano G., Bertoni F.
Genome wide DNA-profiling of HIV-related B-cell lymphomas
Capello D., Scandurra M., Poretti G., Rancoita P. M., Mian M., Gloghini A., Deambrogi C., Martini M., Rossi D., Greiner T. C., Chan W. C., Ponzoni M., Moreno S. M., Piris M. A., Canzonieri V., Spina M., Tirelli U., Inghirami G., Rinaldi A., Zucca E., Favera R. D., Cavalli F., Larocca L. M., Kwee I., Carbone A., Gaidano G., Bertoni F.
Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip
Migliore A., Massafra U., Bizzi E., Vacca F., Martin-Martin S., Granata M., Alimonti A., Tormenta S.
High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients
Pavese I., Satta F., Todi F., Di Palma M., Piergrossi P., Migliore A., Piselli P., Borghesi R., Mancino G., Brunetti E., Alimonti A.
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
Bomben R., Dal Bo M., Capello D., Forconi F., Bertoni F., Maffei R., Laurenti L., Rossi D., Zucca E., Degan M., Marasca R., Efremov D. G., Del Poeta G., Gaidano G., Gattei V.
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
Bomben R., Dal Bo M., Capello D., Forconi F., Bertoni F., Maffei R., Laurenti L., Rossi D., Zucca E., Degan M., Marasca R., Efremov D. G., Del Poeta G., Gaidano G., Gattei V.
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features
Bomben R., Dal-Bo M., Benedetti D., Capello D., Forconi F., Marconi D., Bertoni F., Maffei R., Laurenti L., Rossi D., Del Principe M. I., Luciano F., Sozzi E., Cattarossi I., Zucchetto A., Rossi F. M., Bulian P., Zucca E., Nicoloso M. S., Degan M., Marasca R., Efremov D. G., Del Poeta G., Gaidano G., Gattei V.
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features
Bomben R., Dal-Bo M., Benedetti D., Capello D., Forconi F., Marconi D., Bertoni F., Maffei R., Laurenti L., Rossi D., Del Principe M. I., Luciano F., Sozzi E., Cattarossi I., Zucchetto A., Rossi F. M., Bulian P., Zucca E., Nicoloso M. S., Degan M., Marasca R., Efremov D. G., Del Poeta G., Gaidano G., Gattei V.
iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells
Bellone M., Ceccon M., Grioni M., Jachetti E., Calcinotto A., Napolitano A., Freschi M., Casorati G., Dellabona P.
Viscosupplementation: a suitable option for hip osteoarthritis in young adults
Migliore A., Bizzi E., Massafra U., Vacca F., Alimonti A., Iannessi F., Tormenta S.
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis
Alimonti A., Nardella C., Chen Z., Clohessy J. G., Carracedo A., Trotman L. C., Cheng K., Varmeh S., Kozma S. C., Thomas G., Rosivatz E., Woscholski R., Cognetti F., Scher H. I., Pandolfi P. P.
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
Rinaldi A., Capello D., Scandurra M., Greiner T. C., Chan W. C., Bhagat G., Rossi D., Morra E., Paulli M., Rambaldi A., Rancoita P. M., Inghirami G., Ponzoni M., Moreno S. M., Piris M. A., Mian M., Chigrinova E., Zucca E., Favera R. D., Gaidano G., Kwee I., Bertoni F.
Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma
Rinaldi A., Capello D., Scandurra M., Greiner T. C., Chan W. C., Bhagat G., Rossi D., Morra E., Paulli M., Rambaldi A., Rancoita P. M., Inghirami G., Ponzoni M., Moreno S. M., Piris M. A., Mian M., Chigrinova E., Zucca E., Favera R. D., Gaidano G., Kwee I., Bertoni F.
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort
Bilous N., Bomben R., Dal Bo M., Capello D., Forconi F., Laurenti L., Bertoni F., Efremov D. G., Marasca R., Del Poeta G., Martina Z., Kryachouk I., Dyagil I., Gaidano G., Chumak A., Gattei V., Abramenko I.
Impact of genomic methylation on radiation sensitivity of colorectal carcinoma
Hofstetter B., Niemierko A., Forrer C., Benhattar J., Albertini V., Pruschy M., Bosman F. T., Catapano C. V., Ciernik I. F.
Syk expression patterns differ among B-cell lymphomas
Ponzoni M., Uccella S., Mian M., Rinaldi A., Facchetti F., Pruneri G., Gaidano G., Capella C., Zucca E., Doglioni C., Bertoni F.
Subtle variations in Pten dose determine cancer susceptibility
Alimonti A., Carracedo A., Clohessy J. G., Trotman L. C., Nardella C., Egia A., Salmena L., Sampieri K., Haveman W. J., Brogi E., Richardson A. L., Zhang J., Pandolfi P. P.
The clinical and biological features of a series of immunophenotypic variant of B-CLL
Cro L., Ferrario A., Lionetti M., Bertoni F., Zucal N. N., Nobili L., Fabris S., Todoerti K., Cortelezzi A., Guffanti A., Goldaniga M., Marcheselli L., Neri A., Lambertenghi-Deliliers G., Baldini L.
Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms
Chigrinova E., Kwee I., Rinaldi A., Poretti G., Pruneri G., Neri A., Gaidano G., Ponzoni M., Zucca E., Bertoni F.
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts
Previdi S., Malek A., Albertini V., Riva C., Capella C., Broggini M., Carbone G. M., Rohr J., Catapano C. V.
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts
Previdi S., Malek A., Albertini V., Riva C., Capella C., Broggini M., Carbone G. M., Rohr J., Catapano C. V.
PAMAM dendrimers for siRNA delivery: computational and experimental insights
Pavan G. M., Posocco P., Tagliabue A., Maly M., Malek A., Danani A., Ragg E., Catapano C. V., Pricl S.
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma
Zibellini S., Capello D., Forconi F., Marcatili P., Rossi D., Rattotti S., Franceschetti S., Sozzi E., Cencini E., Marasca R., Baldini L., Tucci A., Bertoni F., Passamonti F., Orlandi E., Varettoni M., Merli M., Rizzi S., Gattei V., Tramontano A., Paulli M., Gaidano G., Arcaini L.
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma
Zibellini S., Capello D., Forconi F., Marcatili P., Rossi D., Rattotti S., Franceschetti S., Sozzi E., Cencini E., Marasca R., Baldini L., Tucci A., Bertoni F., Passamonti F., Orlandi E., Varettoni M., Merli M., Rizzi S., Gattei V., Tramontano A., Paulli M., Gaidano G., Arcaini L.
Serotonin receptor 3A expression in normal and neoplastic B cells
Rinaldi A., Chiaravalli A. M., Mian M., Zucca E., Tibiletti M. G., Capella C., Bertoni F.
Small RNA-directed transcriptional control: new insights into mechanisms and therapeutic applications
Pastori C., Magistri M., Napoli S., Carbone G. M., Catapano C. V.
Small RNA-directed transcriptional control: new insights into mechanisms and therapeutic applications
Pastori C., Magistri M., Napoli S., Carbone G. M., Catapano C. V.
Patterns of survival of follicular lymphomas at a single institution through three decades
Conconi A., Motta M., Bertoni F., Piona C., Stathis A., Wannesson L., Gracia E., Filho V. B., Abreu D. R., Mian M., Froesch P., Mazzucchelli L., Ghielmini M., Cavalli F., Zucca E.
An integrated Bayesian analysis of LOH and copy number data
Rancoita P. M., Hutter M., Bertoni F., Kwee I.
Treatment of gastric marginal zone lymphoma of MALT type
Stathis A., Bertoni F., Zucca E.
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome
Chigrinova E., Mian M., Scandurra M., Greiner T. C., Chan W. C., Vose J. M., Inghirami G., Chiappella A., Baldini L., Ponzoni M., Ferreri A. J., Franceschetti S., Gaidano G., Tucci A., Facchetti F., Lazure T., Lambotte O., Montes-Moreno S., Piris M. A., Nomdedeu J. F., Uccella S., Rancoita P. M., Kwee I., Zucca E., Bertoni F.
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia
Bulian P., Tarnani M., Rossi D., Forconi F., Del Poeta G., Bertoni F., Zucca E., Montillo M., Pozzato G., Deaglio S., D'Arena G., Efremov D., Marasca R., Lauria F., Gattei V., Gaidano G., Laurenti L.
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia
Bulian P., Tarnani M., Rossi D., Forconi F., Del Poeta G., Bertoni F., Zucca E., Montillo M., Pozzato G., Deaglio S., D'Arena G., Efremov D., Marasca R., Lauria F., Gattei V., Gaidano G., Laurenti L.
Viscosupplementation in the management of ankle osteoarthritis: a review
Migliore A., Giovannangeli F., Bizzi E., Massafra U., Alimonti A., Laganà B., Diamanti Picchianti A., Germano V., Granata M., Piscitelli P.
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21
Scandurra M., Mian M., Greiner T. C., Rancoita P. M., De Campos C. P., Chan W. C., Vose J. M., Chigrinova E., Inghirami G., Chiappella A., Baldini L., Ponzoni M., Ferreri A. J., Franceschetti S., Gaidano G., Montes-Moreno S., Piris M. A., Facchetti F., Tucci A., Nomdedeu J. F., Lazure T., Lambotte O., Uccella S., Pinotti G., Pruneri G., Martinelli G., Young K. H., Tibiletti M. G., Rinaldi A., Zucca E., Kwee I., Bertoni F.
Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas
Furlan D., Carnevali I. W., Bernasconi B., Sahnane N., Milani K., Cerutti R., Bertolini V., Chiaravalli A. M., Bertoni F., Kwee I., Pastorino R., Carlo C.
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells
Venetz D., Ponzoni M., Schiraldi M., Ferreri A. J., Bertoni F., Doglioni C., Uguccioni M.
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma
Rinaldi A., Forconi F., Arcaini L., Mian M., Sozzi E., Zibellini S., Baldini L., Franceschetti S., Gaidano G., Marasca R., Mollejo M., Piris M. A., Tucci A., Facchetti F., Bhagat G., Favera R. D., Rancoita P. M., Zucca E., Kwee I., Bertoni F.
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
Rinaldi A., Mian M., Chigrinova E., Arcaini L., Bhagat G., Novak U., Rancoita P. M., De Campos C. P., Forconi F., Gascoyne R. D., Facchetti F., Ponzoni M., Govi S., Ferreri A. J., Mollejo M., Piris M. A., Baldini L., Soulier J., Thieblemont C., Canzonieri V., Gattei V., Marasca R., Franceschetti S., Gaidano G., Tucci A., Uccella S., Tibiletti M. G., Dirnhofer S., Tripodo C., Doglioni C., Dalla Favera R., Cavalli F., Zucca E., Kwee I., Bertoni F.
PTEN level in tumor suppression: how much is too little?
Carracedo A., Alimonti A., Pandolfi P. P.
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Rossi D., Spina V., Deambrogi C., Rasi S., Laurenti L., Stamatopoulos K., Arcaini L., Lucioni M., Rocque G. B., Xu-Monette Z. Y., Visco C., Chang J., Chigrinova E., Forconi F., Marasca R., Besson C., Papadaki T., Paulli M., Larocca L. M., Pileri S. A., Gattei V., Bertoni F., Foà R., Young K. H., Gaidano G.
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation
Rossi D., Spina V., Deambrogi C., Rasi S., Laurenti L., Stamatopoulos K., Arcaini L., Lucioni M., Rocque G. B., Xu-Monette Z. Y., Visco C., Chang J., Chigrinova E., Forconi F., Marasca R., Besson C., Papadaki T., Paulli M., Larocca L. M., Pileri S. A., Gattei V., Bertoni F., Foà R., Young K. H., Gaidano G.
Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas
Capello D., Gloghini A., Martini M., Spina M., Tirelli U., Bertoni F., Rinaldi A., Morra E., Rambaldi A., Sinigaglia F., Larocca L. M., Carbone A.
Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas
Capello D., Gloghini A., Martini M., Spina M., Tirelli U., Bertoni F., Rinaldi A., Morra E., Rambaldi A., Sinigaglia F., Larocca L. M., Carbone A.
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage
Dal-Bo M., Del Giudice I., Bomben R., Capello D., Bertoni F., Forconi F., Laurenti L., Rossi D., Zucchetto A., Pozzato G., Marasca R., Efremov D. G., Guarini A., Del Poeta G., Foà R., Gaidano G., Gattei V.
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage
Dal-Bo M., Del Giudice I., Bomben R., Capello D., Bertoni F., Forconi F., Laurenti L., Rossi D., Zucchetto A., Pozzato G., Marasca R., Efremov D. G., Guarini A., Del Poeta G., Foà R., Gaidano G., Gattei V.
Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from Italian registry
Migliore A., Granata M., Tormenta S., Laganà B., Piscitelli P., Bizzi E., Massafra U., Alimonti A., Maggi C., De Chiara R., Iannessi F., Sanfilippo A., Sotera R., Scapato P., Carducci S., Persod P., Denaro S., Camminiti M., Pagano M. G., Bagnato G., Iolascon G.
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
Rinaldi A., Ponzoni M., Uccella S., Rossi D., Gaidano G., Facchetti F., Pruneri G., Tibiletti M. G., Capella C., Zucca E., Doglioni C., Catapano C., Bertoni F.
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
Rinaldi A., Ponzoni M., Uccella S., Rossi D., Gaidano G., Facchetti F., Pruneri G., Tibiletti M. G., Capella C., Zucca E., Doglioni C., Catapano C., Bertoni F.
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas
Rinaldi A., Ponzoni M., Uccella S., Rossi D., Gaidano G., Facchetti F., Pruneri G., Tibiletti M. G., Capella C., Zucca E., Doglioni C., Catapano C., Bertoni F.
Integrated profiling of diffuse large B-cell lymphoma with 7q gain
Chigrinova E., Mian M., Shen Y., Greiner T. C., Chan W. C., Vose J. M., Inghirami G., Chiappella A., Baldini L., Ponzoni M., Ferreri A. J., Franceschetti S., Gaidano G., Tucci A., Facchetti F., Lazure T., Lambotte O., Montes-Moreno S., Piris M. A., Zucca E., Kwee I., Bertoni F.
Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines
Poretti G., Kwee I., Bernasconi B., Rancoita P. M., Rinaldi A., Capella C., Zucca E., Neri A., Tibiletti M. G., Bertoni F.
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis
Nardella C., Lunardi A., Fedele G., Clohessy J. G., Alimonti A., Kozma S. C., Thomas G., Loda M., Pandolfi P. P.
Genomic profiles of MALT lymphomas: variability across anatomical sites
Kwee I., Rancoita P. M., Rinaldi A., Ferreri A. J., Bhagat G., Gascoyne R. D., Canzonieri V., Gaidano G., Doglioni C., Zucca E., Ponzoni M., Bertoni F.
Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP
Testoni M., Kwee I., Greiner T. C., Montes-Moreno S., Vose J., Chan W. C., Chiappella A., Baldini L., Ferreri A. J., Gaidano G., Mian M., Zucca E., Bertoni F.
Anaplastic lymphoma kinase in human cancer
Barreca A., Lasorsa E., Riera L., Machiorlatti R., Piva R., Ponzoni M., Kwee I., Bertoni F., Piccaluga P. P., Pileri S. A., Inghirami G.
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
Dal Bo M., Rossi F. M., Rossi D., Deambrogi C., Bertoni F., Del Giudice I., Palumbo G., Nanni M., Rinaldi A., Kwee I., Tissino E., Corradini G., Gozzetti A., Cencini E., Ladetto M., Coletta A. M., Luciano F., Bulian P., Pozzato G., Laurenti L., Forconi F., Di Raimondo F., Marasca R., Del Poeta G., Gaidano G., Foà R., Guarini A., Gattei V.
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia
Dal Bo M., Rossi F. M., Rossi D., Deambrogi C., Bertoni F., Del Giudice I., Palumbo G., Nanni M., Rinaldi A., Kwee I., Tissino E., Corradini G., Gozzetti A., Cencini E., Ladetto M., Coletta A. M., Luciano F., Bulian P., Pozzato G., Laurenti L., Forconi F., Di Raimondo F., Marasca R., Del Poeta G., Gaidano G., Foà R., Guarini A., Gattei V.
Fluorescence in situ hybridization (FISH) for evaluating residual disease in Philadelphia chromosome-positive chronic myeloid leukemia during interferon alpha therapy
Foa P., Pomati M., Ribera S., Caldiera S., Bertoni F., Fornier M., Maiolo A.
Chronic myeloid leukemia treated with busulfan
Foa P., Iurlo A., Ribera S., Damilano I., Caldiera S., Fornier M., Bertoni F., Maiolo A.
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia
Rasi S., Bruscaggin A., Rinaldi A., Cresta S., Fangazio M., De Paoli L., Monti S., Gargiulo E., Kwee I., Foà R., Bertoni F., Gaidano G., Rossi D.
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia
Rasi S., Bruscaggin A., Rinaldi A., Cresta S., Fangazio M., De Paoli L., Monti S., Gargiulo E., Kwee I., Foà R., Bertoni F., Gaidano G., Rossi D.
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Renner C., Zinzani P. L., Gressin R., Klingbiel D., Dietrich P. Y., Hitz F., Bargetzi M., Mingrone W., Martinelli G., Trojan A., Bouabdallah K., Lohri A., Gyan E., Biaggi C., Cogliatti S., Bertoni F., Ghielmini M., Brauchli P., Ketterer N.
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., Cresta S., Gargiulo E., Forconi F., Guarini A., Arcaini L., Paulli M., Laurenti L., Larocca L. M., Marasca R., Gattei V., Oscier D., Bertoni F., Mullighan C. G., Foá R., Pasqualucci L., Rabadan R., Dalla-Favera R., Gaidano G.
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation
Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., Cresta S., Gargiulo E., Forconi F., Guarini A., Arcaini L., Paulli M., Laurenti L., Larocca L. M., Marasca R., Gattei V., Oscier D., Bertoni F., Mullighan C. G., Foá R., Pasqualucci L., Rabadan R., Dalla-Favera R., Gaidano G.
Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype
Mian M., Rinaldi A., Mensah A. A., Rossi D., Ladetto M., Forconi F., Marasca R., Gattei V., Zucca E., Cavalli F., Gaidano G., Kwee I., Bertoni F.
Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype
Mian M., Rinaldi A., Mensah A. A., Rossi D., Ladetto M., Forconi F., Marasca R., Gattei V., Zucca E., Cavalli F., Gaidano G., Kwee I., Bertoni F.
Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion
Mian M., Scandurra M., Chigrinova E., Shen Y., Inghirami G., Greiner T. C., Chan W. C., Vose J. M., Testoni M., Chiappella A., Baldini L., Ponzoni M., Ferreri A. J. M., Franceschetti S., Gaidano G., Montes-Moreno S., Piris M. A., Facchetti F., Tucci A., Nomdedeu J. F., Lazure T., Uccella S., Tibiletti M. G., Zucca E., Kwee I., Bertoni F.
Pro-senescence therapy for cancer treatment
Nardella C., Clohessy J. G., Alimonti A., Pandolfi P. P.
Epigenetics in prostate cancer: biologic and clinical relevance
Jerónimo C., Bastian P. J., Bjartell A., Carbone G. M., Catto J. W., Clark S. J., Henrique R., Nelson W. G., Shariat S. F.
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis
Rossi D., Spina V., Forconi F., Capello D., Fangazio M., Rasi S., Martini M., Gattei V., Ramponi A., Larocca L. M., Bertoni F., Gaidano G.
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis
Rossi D., Spina V., Forconi F., Capello D., Fangazio M., Rasi S., Martini M., Gattei V., Ramponi A., Larocca L. M., Bertoni F., Gaidano G.
Active-targeted nanotherapy strategies for prostate cancer
Katsogiannou M., Peng L., Catapano C. V., Rocchi P.
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma
Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., Spina V., Bruscaggin A., Monti S., Cerri M., Cresta S., Fangazio M., Arcaini L., Lucioni M., Marasca R., Thieblemont C., Capello D., Facchetti F., Kwee I., Pileri S. A., Foà R., Bertoni F., Dalla-Favera R., Pasqualucci L., Gaidano G.
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma
Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., Spina V., Bruscaggin A., Monti S., Cerri M., Cresta S., Fangazio M., Arcaini L., Lucioni M., Marasca R., Thieblemont C., Capello D., Facchetti F., Kwee I., Pileri S. A., Foà R., Bertoni F., Dalla-Favera R., Pasqualucci L., Gaidano G.
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M., Fangazio M., Vaisitti T., Monti S., Chiaretti S., Guarini A., Del Giudice I., Cerri M., Cresta S., Deambrogi C., Gargiulo E., Gattei V., Forconi F., Bertoni F., Deaglio S., Rabadan R., Pasqualucci L., Foà R., Dalla-Favera R., Gaidano G.
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M., Fangazio M., Vaisitti T., Monti S., Chiaretti S., Guarini A., Del Giudice I., Cerri M., Cresta S., Deambrogi C., Gargiulo E., Gattei V., Forconi F., Bertoni F., Deaglio S., Rabadan R., Pasqualucci L., Foà R., Dalla-Favera R., Gaidano G.
Absence of NOTCH1 gene mutations in MALT lymphomas
Mensah A. A., Rinaldi A., Ponzoni M., Canzonieri V., Uccella S., Rossi D., Bhagat G., Gaidano G., Zucca E., Bertoni F.
Absence of NOTCH1 gene mutations in MALT lymphomas
Mensah A. A., Rinaldi A., Ponzoni M., Canzonieri V., Uccella S., Rossi D., Bhagat G., Gaidano G., Zucca E., Bertoni F.
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
Ferrero S., Capello D., Svaldi M., Boi M., Gatti D., Drandi D., Rossi D., Barbiero S., Mantoan B., Mantella E., Zanni M., Ghione P., Larocca A., Passera R., Bertoni F., Gattei V., Forconi F., Laurenti L., Del Poeta G., Marasca R., Cortelazzo S., Gaidano G., Palumbo A., Boccadoro M., Ladetto M.
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes
Ferrero S., Capello D., Svaldi M., Boi M., Gatti D., Drandi D., Rossi D., Barbiero S., Mantoan B., Mantella E., Zanni M., Ghione P., Larocca A., Passera R., Bertoni F., Gattei V., Forconi F., Laurenti L., Del Poeta G., Marasca R., Cortelazzo S., Gaidano G., Palumbo A., Boccadoro M., Ladetto M.
PTEN breast cancer susceptibility: a matter of dose
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
Bulian P., Rossi D., Forconi F., Del Poeta G., Bertoni F., Zucca E., Montillo M., Pozzato G., D'Arena G., Efremov D. G., Marasca R., Lauria F., Gaidano G., Gattei V., Laurenti L.
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
Bulian P., Rossi D., Forconi F., Del Poeta G., Bertoni F., Zucca E., Montillo M., Pozzato G., D'Arena G., Efremov D. G., Marasca R., Lauria F., Gaidano G., Gattei V., Laurenti L.
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., Chiaretti S., Del Giudice I., Fabbri G., Bruscaggin A., Spina V., Deambrogi C., Marinelli M., Famà R., Greco M., Daniele G., Forconi F., Gattei V., Bertoni F., Deaglio S., Pasqualucci L., Guarini A., Dalla-Favera R., Foà R., Gaidano G.
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., Chiaretti S., Del Giudice I., Fabbri G., Bruscaggin A., Spina V., Deambrogi C., Marinelli M., Famà R., Greco M., Daniele G., Forconi F., Gattei V., Bertoni F., Deaglio S., Pasqualucci L., Guarini A., Dalla-Favera R., Foà R., Gaidano G.
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy
Calcinotto A., Grioni M., Jachetti E., Curnis F., Mondino A., Parmiani G., Corti A., Bellone M.
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression
Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P., Brino L., Oudet P., Seiler R., Thalman G. N., Roggero E., Sarti M., Pinton S., Mello-Grand M., Chiorino G., Catapano C. V., Carbone G. M., Bonapace I. M.
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression
Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P., Brino L., Oudet P., Seiler R., Thalman G. N., Roggero E., Sarti M., Pinton S., Mello-Grand M., Chiorino G., Catapano C. V., Carbone G. M., Bonapace I. M.
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
Conconi A., Ponzio C., Lobetti-Bodoni C., Motta M., Rancoita P. M., Stathis A., Moccia A. A., Mazzucchelli L., Bertoni F., Ghielmini M., Cavalli F., Zucca E.
Studies on the biology, histology and cytogenetics of two sublines of a murine ovarian reticular cell sarcoma : Biology of M5 and R16 murine tumor
Donelli M. G., Dolfini E., Catapano C., Finazzi M., Mandelli G. C., Volontè M., Fuhrman Conti A. M.
Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma
Traverse-Glehen A., Bertoni F., Thieblemont C., Zucca E., Coiffier B., Berger F., Salles G.
Splenic marginal zone lymphoma: current knowledge and future directions
Thieblemont C., Davi F., Noguera M. E., Brière J., Bertoni F., Zucca E., Traverse-Glehen A., Felman P., Berger F., Salles G., Coiffier B.
Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells
Boi M., Stathis A., Zucca E., Inghirami G., Bertoni F.
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes
Calcinotto A., Filipazzi P., Grioni M., Iero M., De Milito A., Ricupito A., Cova A., Canese R., Jachetti E., Rossetti M., Huber V., Parmiani G., Generoso L., Santinami M., Borghi M., Fais S., Bellone M., Rivoltini L.
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens
Parma G., Mancari R., Del Conte G., Scambia G., Gadducci A., Hess D., Katsaros D., Sessa C., Rinaldi A., Bertoni F., Vitali A., Catapano C. V., Marsoni S., van de Velde H., Colombo N.
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens
Parma G., Mancari R., Del Conte G., Scambia G., Gadducci A., Hess D., Katsaros D., Sessa C., Rinaldi A., Bertoni F., Vitali A., Catapano C. V., Marsoni S., van de Velde H., Colombo N.
MYD88 somatic mutations in MALT lymphomas
Li Z. M., Rinaldi A., Cavalli A., Mensah A. A., Ponzoni M., Gascoyne R. D., Bhagat G., Zucca E., Bertoni F.
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma
Agnelli L., Mereu E., Pellegrino E., Limongi T., Kwee I., Bergaggio E., Ponzoni M., Zamò A., Iqbal J., Piccaluga P. P., Neri A., Chan W. C., Pileri S., Bertoni F., Inghirami G., Piva R.
Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial
Ferreri A. J., Govi S., Pasini E., Mappa S., Bertoni F., Zaja F., Montalbán C., Stelitano C., Cabrera M. E., Giordano Resti A., Politi L. S., Doglioni C., Cavalli F., Zucca E., Ponzoni M., Dolcetti R.
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., Monti S., Vaisitti T., Arruga F., Famà R., Ciardullo C., Greco M., Cresta S., Piranda D., Holmes A., Fabbri G., Messina M., Rinaldi A., Wang J., Agostinelli C., Piccaluga P. P., Lucioni M., Tabbò F., Serra R., Franceschetti S., Deambrogi C., Daniele G., Gattei V., Marasca R., Facchetti F., Arcaini L., Inghirami G., Bertoni F., Pileri S. A., Deaglio S., Foà R., Dalla-Favera R., Pasqualucci L., Rabadan R., Gaidano G.
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development
Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., Monti S., Vaisitti T., Arruga F., Famà R., Ciardullo C., Greco M., Cresta S., Piranda D., Holmes A., Fabbri G., Messina M., Rinaldi A., Wang J., Agostinelli C., Piccaluga P. P., Lucioni M., Tabbò F., Serra R., Franceschetti S., Deambrogi C., Daniele G., Gattei V., Marasca R., Facchetti F., Arcaini L., Inghirami G., Bertoni F., Pileri S. A., Deaglio S., Foà R., Dalla-Favera R., Pasqualucci L., Rabadan R., Gaidano G.
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia
De Paoli L., Cerri M., Monti S., Rasi S., Spina V., Bruscaggin A., Greco M., Ciardullo C., Famà R., Cresta S., Maffei R., Ladetto M., Martini M., Laurenti L., Forconi F., Marasca R., Larocca L. M., Bertoni F., Gaidano G., Rossi D.
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia
De Paoli L., Cerri M., Monti S., Rasi S., Spina V., Bruscaggin A., Greco M., Ciardullo C., Famà R., Cresta S., Maffei R., Ladetto M., Martini M., Laurenti L., Forconi F., Marasca R., Larocca L. M., Bertoni F., Gaidano G., Rossi D.
Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
Copie-Bergman C., Wotherspoon A. C., Capella C., Motta T., Pedrinis E., Pileri S. A., Bertoni F., Conconi A., Zucca E., Ponzoni M., Ferreri A. J.
Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis
Li Z. M., Spagnuolo L., Mensah A. A., Rinaldi A., Bhagat G., Zucca E., Doglioni C., Ferreri A. J., Ponzoni M., Bertoni F.
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C., Deambrogi C., Khiabanian H., Serra R., Bertoni F., Forconi F., Laurenti L., Marasca R., Dal-Bo M., Rossi F. M., Bulian P., Nomdedeu J., Del Poeta G., Gattei V., Pasqualucci L., Rabadan R., Foà R., Dalla-Favera R., Gaidano G.
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
Rossi D., Rasi S., Spina V., Bruscaggin A., Monti S., Ciardullo C., Deambrogi C., Khiabanian H., Serra R., Bertoni F., Forconi F., Laurenti L., Marasca R., Dal-Bo M., Rossi F. M., Bulian P., Nomdedeu J., Del Poeta G., Gattei V., Pasqualucci L., Rabadan R., Foà R., Dalla-Favera R., Gaidano G.
Risk factors of central nervous system relapse in mantle cell lymphoma
Conconi A., Franceschetti S., Lobetti-Bodoni C., Stathis A., Margiotta-Casaluci G., Ramponi A., Mazzucchelli L., Bertoni F., Ghielmini M., Gaidano G., Cavalli F., Zucca E.
Genome-wide DNA profiling of HIV-related B-cell lymphomas
Rinaldi A., Capello D., Zucca E., Gaidano G., Bertoni F.
The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors
Bellone M., Calcinotto A., Filipazzi P., De Milito A., Fais S., Rivoltini L.
Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings
Ricupito A., Grioni M., Calcinotto A., Hess Michelini R., Longhi R., Mondino A., Bellone M.
Daunomycin-TFO Conjugates for Downregulation of Gene Expression
Capobianco M. L., Catapano C. V.
Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation
Malek A., Gyorffy B., Catapano C. V., Schäfer R.
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma
Tabbò F., Ponzoni M., Rabadan R., Bertoni F., Inghirami G.
Genome-wide high resolution DNA profiling of hairy cell leukaemia
Rinaldi A., Kwee I., Young K. H., Zucca E., Gaidano G., Forconi F., Bertoni F.
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses
Jachetti E., Mazzoleni S., Grioni M., Ricupito A., Brambillasca C., Generoso L., Calcinotto A., Freschi M., Mondino A., Galli R., Bellone M.
Prognostic impact of monocyte count at presentation in mantle cell lymphoma
von Hohenstaufen K. A., Conconi A., de Campos C. P., Franceschetti S., Bertoni F., Margiotta Casaluci G., Stathis A., Ghielmini M., Stussi G., Cavalli F., Gaidano G., Zucca E.
Coral aquaculture to support drug discovery
Leal M. C., Calado R., Sheridan C., Alimonti A., Osinga R.
Coral aquaculture to support drug discovery
Leal M. C., Calado R., Sheridan C., Alimonti A., Osinga R.
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
Bonetti P., Testoni M., Scandurra M., Ponzoni M., Piva R., Mensah A. A., Rinaldi A., Kwee I., Tibiletti M. G., Iqbal J., Greiner T. C., Chan W. C., Gaidano G., Piris M. A., Cavalli F., Zucca E., Inghirami G., Bertoni F.
Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics
Liu X., Liu C., Catapano C. V., Peng L., Zhou J., Rocchi P.
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma
Boi M., Rinaldi A., Kwee I., Bonetti P., Todaro M., Tabbò F., Piva R., Rancoita P. M., Matolcsy A., Timar B., Tousseyn T., Rodríguez-Pinilla S. M., Piris M. A., Beà S., Campo E., Bhagat G., Swerdlow S. H., Rosenwald A., Ponzoni M., Young K. H., Piccaluga P. P., Dummer R., Pileri S., Zucca E., Inghirami G., Bertoni F.
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma
Bouska A., McKeithan T. W., Deffenbacher K. E., Lachel C., Wright G. W., Iqbal J., Smith L. M., Zhang W., Kucuk C., Rinaldi A., Bertoni F., Fitzgibbon J., Fu K., Weisenburger D. D., Greiner T. C., Dave B. J., Gascoyne R. D., Rosenwald A., Ott G., Campo E., Rimsza L. M., Delabie J., Jaffe E. S., Braziel R. M., Connors J. M., Staudt L. M., Chan W. C.
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes
Bellone M., Calcinotto A.
Boosting anticancer vaccines: Too much of a good thing?
Ricupito A., Grioni M., Calcinotto A., Bellone M.
Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices
de Campos C. P., Rancoita P. M., Kwee I., Zucca E., Zaffalon M., Bertoni F.
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation
Martínez N., Almaraz C., Vaqué J. P., Varela I., Derdak S., Beltran S., Mollejo M., Campos-Martin Y., Agueda L., Rinaldi A., Kwee I., Gut M., Blanc J., Oscier D., Strefford J. C., Martinez-Lopez J., Salar A., Sole F., Rodriguez-Peralto J. L., Diez-Tascón C., García J. F., Fraga M., Sebastián E., Alvés J., Menárguez J., González-Carreró J., Casado L. F., Bayes M., Bertoni F., Gut I., Piris M. A.
Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia
Ronchetti D., Tuana G., Rinaldi A., Agnelli L., Cutrona G., Mosca L., Fabris S., Matis S., Colombo M., Gentile M., Recchia A. G., Kwee I., Bertoni F., Morabito F., Ferrarini M., Neri A.
MYC network mutations in high-risk chronic lymphocytic leukaemia
Monti S., Deambrogi C., Rinaldi A., Bertoni F., Gaidano G., Rossi D.
MYC network mutations in high-risk chronic lymphocytic leukaemia
Monti S., Deambrogi C., Rinaldi A., Bertoni F., Gaidano G., Rossi D.
The management of nongastric MALT lymphomas
Zucca E., Stathis A., Bertoni F.
PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas
Boi M., Zucca E., Inghirami G., Bertoni F.
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma
Ok C. Y., Chen J., Xu-Monette Z. Y., Tzankov A., Manyam G. C., Li L., Visco C., Montes-Moreno S., Dybkær K., Chiu A., Orazi A., Zu Y., Bhagat G., Richards K. L., Hsi E. D., Choi W. W., van Krieken J. H., Huh J., Zhao X., Ponzoni M., Ferreri A. J., Bertoni F., Farnen J. P., Møller M. B., Piris M. A., Winter J. N., Medeiros L. J., Young K. H.
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri D., Toso A., Chen J. J., Sarti M., Pinton S., Jost T. R., D'Antuono R., Montani E., Garcia-Escudero R., Guccini I., Da Silva-Alvarez S., Collado M., Eisenberger M., Zhang Z., Catapano C., Grassi F., Alimonti A.
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri D., Toso A., Chen J. J., Sarti M., Pinton S., Jost T. R., D'Antuono R., Montani E., Garcia-Escudero R., Guccini I., Da Silva-Alvarez S., Collado M., Eisenberger M., Zhang Z., Catapano C., Grassi F., Alimonti A.
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri D., Toso A., Chen J. J., Sarti M., Pinton S., Jost T. R., D'Antuono R., Montani E., Garcia-Escudero R., Guccini I., Da Silva-Alvarez S., Collado M., Eisenberger M., Zhang Z., Catapano C., Grassi F., Alimonti A.
Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas
Zucca E., Bertoni F., Vannata B., Cavalli F.
The transcription factor ETS1 in lymphomas: friend or foe?
Testoni M., Chung E. Y., Priebe V., Bertoni F.
Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
Chilà R., Basana A., Lupi M., Guffanti F., Gaudio E., Rinaldi A., Cascione L., Restelli V., Tarantelli C., Bertoni F., Damia G., Carrassa L.
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation
Abate F., Todaro M., van der Krogt J. A., Boi M., Landra I., Machiorlatti R., Tabbò F., Messana K., Abele C., Barreca A., Novero D., Gaudiano M., Aliberti S., Di Giacomo F., Tousseyn T., Lasorsa E., Crescenzo R., Bessone L., Ficarra E., Acquaviva A., Rinaldi A., Ponzoni M., Longo D. L., Aime S., Cheng M., Ruggeri B., Piccaluga P. P., Pileri S., Tiacci E., Falini B., Pera-Gresely B., Cerchietti L., Iqbal J., Chan W. C., Shultz L. D., Kwee I., Piva R., Wlodarska I., Rabadan R., Bertoni F., Inghirami G.
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas
Boi M., Zucca E., Inghirami G., Bertoni F.
Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL
Iacovelli S., Hug E., Bennardo S., Duehren-von Minden M., Gobessi S., Rinaldi A., Suljagic M., Bilbao D., Bolasco G., Eckl-Dorna J., Niederberger V., Autore F., Sica S., Laurenti L., Wang H., Cornall R. J., Clarke S. H., Croce C. M., Bertoni F., Jumaa H., Efremov D. G.
Genetic lesions in diffuse large B-cell lymphomas
Testoni M., Zucca E., Young K. H., Bertoni F.
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Boi M., Gaudio E., Bonetti P., Kwee I., Bernasconi E., Tarantelli C., Rinaldi A., Testoni M., Cascione L., Ponzoni M., Mensah A. A., Stathis A., Stussi G., Riveiro M. E., Herait P., Inghirami G., Cvitkovic E., Zucca E., Bertoni F.
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
Mensah A. A., Kwee I., Gaudio E., Rinaldi A., Ponzoni M., Cascione L., Fossati G., Stathis A., Zucca E., Caprini G., Bertoni F.
Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor
Vesci L., Bernasconi E., Milazzo F. M., De Santis R., Gaudio E., Kwee I., Rinaldi A., Pace S., Carollo V., Giannini G., Bertoni F.
Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
Calcinotto A., Ponzoni M., Ria R., Grioni M., Cattaneo E., Villa I., Sabrina Bertilaccio M. T., Chesi M., Rubinacci A., Tonon G., Bergsagel P. L., Vacca A., Bellone M.
The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models
Bernasconi E., Gaudio E., Kwee I., Rinaldi A., Cascione L., Tarantelli C., Mensah A. A., Stathis A., Zucca E., Vesci L., Giannini G., Bertoni F.
Life expectancy of young adults with follicular lymphoma
Conconi A., Lobetti-Bodoni C., Montoto S., Lopez-Guillermo A., Coutinho R., Matthews J., Franceschetti S., Bertoni F., Moccia A., Rancoita P. M., Gribben J., Cavalli F., Gaidano G., Lister T. A., Montserrat E., Ghielmini M., Zucca E.
Histologic transformation in marginal zone lymphomas†
Conconi A., Franceschetti S., Aprile von Hohenstaufen K., Margiotta-Casaluci G., Stathis A., Moccia A. A., Bertoni F., Ramponi A., Mazzucchelli L., Cavalli F., Gaidano G., Zucca E.
Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
Restelli V., Chilà R., Lupi M., Rinaldi A., Kwee I., Bertoni F., Damia G., Carrassa L.
Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma
Ferretti E., Di Carlo E., Ognio E., Guarnotta C., Bertoni F., Corcione A., Prigione I., Fraternali-Orcioni G., Ribatti D., Ravetti J. L., Ponzoni M., Tripodo C., Pistoia V.
Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts
Scarfò I., Pellegrino E., Mereu E., Kwee I., Agnelli L., Bergaggio E., Garaffo G., Vitale N., Caputo M., Machiorlatti R., Circosta P., Abate F., Barreca A., Novero D., Mathew S., Rinaldi A., Tiacci E., Serra S., Deaglio S., Neri A., Falini B., Rabadan R., Bertoni F., Inghirami G., Piva R.
EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Civenni G., Longoni N., Costales P., Dallavalle C., García Inclán C., Albino D., Nuñez L. E., Morís F., Carbone G. M., Catapano C. V.
EC-70124, a Novel Glycosylated Indolocarbazole Multikinase Inhibitor, Reverts Tumorigenic and Stem Cell Properties in Prostate Cancer by Inhibiting STAT3 and NF-κB
Civenni G., Longoni N., Costales P., Dallavalle C., García Inclán C., Albino D., Nuñez L. E., Morís F., Carbone G. M., Catapano C. V.
Targeting vasculogenesis to prevent progression in multiple myeloma
Moschetta M., Mishima Y., Kawano Y., Manier S., Paiva B., Palomera L., Aljawai Y., Calcinotto A., Unitt C., Sahin I., Sacco A., Glavey S., Shi J., Reagan M. R., Prosper F., Bellone M., Chesi M., Bergsagel L. P., Vacca A., Roccaro A. M., Ghobrial I. M.
Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients
Bianco M., Gasparri A. M., Colombo B., Curnis F., Girlanda S., Ponzoni M., Bertilaccio M. T., Calcinotto A., Sacchi A., Ferrero E., Ferrarini M., Chesi M., Bergsagel P. L., Bellone M., Tonon G., Ciceri F., Marcatti M., Caligaris-Cappio F., Corti A.
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
Gaudio E., Tarantelli C., Kwee I., Barassi C., Bernasconi E., Rinaldi A., Ponzoni M., Cascione L., Targa A., Stathis A., Goodstal S., Zucca E., Bertoni F.
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
Zucca E., Bertoni F.
Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines
Bernasconi E., Gaudio E., Kwee I., Bertoni F.
The genetic landscape of dural marginal zone lymphomas
Ganapathi K. A., Jobanputra V., Iwamoto F., Jain P., Chen J., Cascione L., Nahum O., Levy B., Xie Y., Khattar P., Hoehn D., Bertoni F., Murty V. V., Pittaluga S., Jaffe E. S., Alobeid B., Mansukhani M. M., Bhagat G.
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
Pizzi M., Boi M., Bertoni F., Inghirami G.
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Dallavalle C., Albino D., Civenni G., Merulla J., Ostano P., Mello-Grand M., Rossi S., Losa M., D'Ambrosio G., Sessa F., Thalmann G. N., Garcia-Escudero R., Zitella A., Chiorino G., Catapano C. V., Carbone G. M.
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Dallavalle C., Albino D., Civenni G., Merulla J., Ostano P., Mello-Grand M., Rossi S., Losa M., D'Ambrosio G., Sessa F., Thalmann G. N., Garcia-Escudero R., Zitella A., Chiorino G., Catapano C. V., Carbone G. M.
IAP antagonists induce anti-tumor immunity in multiple myeloma
Chesi M., Mirza N. N., Garbitt V. M., Sharik M. E., Dueck A. C., Asmann Y. W., Akhmetzyanova I., Kosiorek H. E., Calcinotto A., Riggs D. L., Keane N., Ahmann G. J., Morrison K. M., Fonseca R., Lacy M. Q., Dingli D., Kumar S. K., Ailawadhi S., Dispenzieri A., Buadi F., Gertz M. A., Reeder C. B., Lin Y., Chanan-Khan A. A., Stewart A. K., Fooksman D., Bergsagel P. L.
Staining the target: CD37 expression in lymphomas
Bertoni F., Stathis A.
Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth
Bujisic B., De Gassart A., Tallant R., Demaria O., Zaffalon L., Chelbi S., Gilliet M., Bertoni F., Martinon F.
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up
Ghione P., Genuardi E., Rossi D., Drandi D., Mantoan B., Barbero D., Bernocco E., Monitillo L., Cerri M., Ruggeri M., Omede P., Deambrogi C., De Paoli L., Passera R., Coscia M., Cavallo F., Massaia M., Boccadoro M., Gaidano G., Ladetto M., Ferrero S.
Let's give BACH2 a breath of fresh air
TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line
Gaudio E., Paduano F., Pinton S., D'Agostino S., Rocca R., Costa G., Ngankeu A., Aqeilan R. I., Croce C. M., Bertoni F., Alcaro S., Trapasso F.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Tarantelli C., Gaudio E., Arribas A. J., Kwee I., Hillmann P., Rinaldi A., Cascione L., Spriano F., Bernasconi E., Guidetti F., Carrassa L., Pittau R. B., Beaufils F., Ritschard R., Rageot D., Sele A., Dossena B., Rossi F. M., Zucchetto A., Taborelli M., Gattei V., Rossi D., Stathis A., Stussi G., Broggini M., Wymann M. P., Wicki A., Zucca E., Cmiljanovic V., Fabbro D., Bertoni F.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Tarantelli C., Gaudio E., Arribas A. J., Kwee I., Hillmann P., Rinaldi A., Cascione L., Spriano F., Bernasconi E., Guidetti F., Carrassa L., Pittau R. B., Beaufils F., Ritschard R., Rageot D., Sele A., Dossena B., Rossi F. M., Zucchetto A., Taborelli M., Gattei V., Rossi D., Stathis A., Stussi G., Broggini M., Wymann M. P., Wicki A., Zucca E., Cmiljanovic V., Fabbro D., Bertoni F.
ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration
Puddinu V., Casella S., Radice E., Thelen S., Dirnhofer S., Bertoni F., Thelen M.
BET Proteins as Targets for Anticancer Treatment
Stathis A., Bertoni F.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., Bono J., Carracedo A., Alimonti A.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., Bono J., Carracedo A., Alimonti A.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., Bono J., Carracedo A., Alimonti A.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., Bono J., Carracedo A., Alimonti A.
Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., Bono J., Carracedo A., Alimonti A.
Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Zabala-Letona A., Arruabarrena-Aristorena A., Martín-Martín N., Fernandez-Ruiz S., Sutherland J. D., Clasquin M., Tomas-Cortazar J., Jimenez J., Torres I., Quang P., Ximenez-Embun P., Bago R., Ugalde-Olano A., Loizaga-Iriarte A., Lacasa-Viscasillas I., Unda M., Torrano V., Cabrera D., van Liempd S. M., Cendon Y., Castro E., Murray S., Revandkar A., Alimonti A., Zhang Y., Barnett A., Lein G., Pirman D., Cortazar A. R., Arreal L., Prudkin L., Astobiza I., Valcarcel-Jimenez L., Zuñiga-García P., Fernandez-Dominguez I., Piva M., Caro-Maldonado A., Sánchez-Mosquera P., Castillo-Martín M., Serra V., Beraza N., Gentilella A., Thomas G., Azkargorta M., Elortza F., Farràs R., Olmos D., Efeyan A., Anguita J., Muñoz J., Falcón-Pérez J. M., Barrio R., Macarulla T., Mato J. M., Martinez-Chantar M. L., Cordon-Cardo C., Aransay A. M., Marks K., Baselga J., Tabernero J., Nuciforo P., Manning B. D., Marjon K., Carracedo A.
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Spina V., Bruscaggin A., Cuccaro A., Martini M., Di Trani M., Forestieri G., Manzoni M., Condoluci A., Arribas A., Terzi-Di-Bergamo L., Locatelli S. L., Cupelli E., Ceriani L., Moccia A. A., Stathis A., Nassi L., Deambrogi C., Diop F., Guidetti F., Cocomazzi A., Annunziata S., Rufini V., Giordano A., Neri A., Boldorini R., Gerber B., Bertoni F., Ghielmini M., Stüssi G., Santoro A., Cavalli F., Zucca E., Larocca L. M., Gaidano G., Hohaus S., Carlo-Stella C., Rossi D.
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
Spina V., Bruscaggin A., Cuccaro A., Martini M., Di Trani M., Forestieri G., Manzoni M., Condoluci A., Arribas A., Terzi-Di-Bergamo L., Locatelli S. L., Cupelli E., Ceriani L., Moccia A. A., Stathis A., Nassi L., Deambrogi C., Diop F., Guidetti F., Cocomazzi A., Annunziata S., Rufini V., Giordano A., Neri A., Boldorini R., Gerber B., Bertoni F., Ghielmini M., Stüssi G., Santoro A., Cavalli F., Zucca E., Larocca L. M., Gaidano G., Hohaus S., Carlo-Stella C., Rossi D.
Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides
Bergmann T. J., Fregno I., Fumagalli F., Rinaldi A., Bertoni F., Boersema P. J., Picotti P., Molinari M.
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
Gerber B., Manzoni M., Spina V., Bruscaggin A., Lionetti M., Fabris S., Barbieri M., Ciceri G., Pompa A., Forestieri G., Lerch E., Servida P., Bertoni F., Zucca E., Ghielmini M., Cortelezzi A., Cavalli F., Stussi G., Baldini L., Rossi D., Neri A.
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias
Gerber B., Manzoni M., Spina V., Bruscaggin A., Lionetti M., Fabris S., Barbieri M., Ciceri G., Pompa A., Forestieri G., Lerch E., Servida P., Bertoni F., Zucca E., Ghielmini M., Cortelezzi A., Cavalli F., Stussi G., Baldini L., Rossi D., Neri A.
Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia
Innocenti I., Rossi D., Trapè G., Autore F., Larocca L. M., Gomes V., Cerri M., Falcucci P., Sica S., Gaidano G., Laurenti L.
Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression
Cortesi F., Delfanti G., Grilli A., Calcinotto A., Gorini F., Pucci F., Lucianò R., Grioni M., Recchia A., Benigni F., Briganti A., Salonia A., De Palma M., Bicciato S., Doglioni C., Bellone M., Casorati G., Dellabona P.
Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?
Condoluci A., Rossi D.
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease
Raponi S., Del Giudice I., Ilari C., Cafforio L., Messina M., Cappelli L. V., Bonina S., Piciocchi A., Marinelli M., Peragine N., Mariglia P., Mauro F. R., Rigolin G. M., Rossi F., Bomben R., Dal Bo M., Del Poeta G., Diop F., Favini C., Rossi D., Gaidano G., Cuneo A., Gattei V., Guarini A., Foá R.
Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery
Civenni G., Carbone G. M., Catapano C. V.
Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery
Civenni G., Carbone G. M., Catapano C. V.
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
Gentile M., Shanafelt T. D., Mauro F. R., Reda G., Rossi D., Laurenti L., Del Principe M. I., Cutrona G., Angeletti I., Coscia M., Herishanu Y., Chiarenza A., Molica S., Ciolli S., Goldschmidt N., Angrilli F., Giordano A., Rago A., Bairey O., Tripepi G., Chaffee K. G., Sameer P. A., Vigna E., Zirlik K., Shvidel L., Innocenti I., Recchia A. G., Di Raimondo F., Del Poeta G., Cortelezzi A., Neri A., Ferrarini M., Gaidano G., Kay N. E., Polliack A., Foà R., Morabito F.
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz D. M., Scherer F., Jin M. C., Soo J., Craig A. F. M., Esfahani M. S., Chabon J. J., Stehr H., Liu C. L., Tibshirani R., Maeda L. S., Gupta N. K., Khodadoust M. S., Advani R. H., Levy R., Newman A. M., Dührsen U., Hüttmann A., Meignan M., Casasnovas R. O., Westin J. R., Roschewski M., Wilson W. H., Gaidano G., Rossi D., Diehn M., Alizadeh A. A.
T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways
Paduano F., Gaudio E., Mensah A. A., Pinton S., Bertoni F., Trapasso F.
Methods for Measuring ctDNA in Lymphomas
Rossi D., Condoluci A., Spina V., Gaidano G.
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study
Ghilardi G., Pabst T., Jeker B., Müller R., Cairoli A., Müller A. M. S., Bargetzi M., Hitz F., Baldomero H., Heim D., Schmidt A., Rossi D., Ghielmini M., Wannesson L., Lerch E., Samaras P., Schanz U., Passweg J. R., Stussi G., Kleber M., Gerber B.
The involvement of microRNA in the pathogenesis of Richter syndrome
Van Roosbroeck K., Bayraktar R., Calin S., Bloehdorn J., Dragomir M. P., Okubo K., Bertilaccio M. T. S., Zupo S., You M. J., Gaidano G., Rossi D., Chen S. S., Chiorazzi N., Thompson P. A., Ferrajoli A., Bertoni F., Stilgenbauer S., Keating M. J., Calin G. A.
The involvement of microRNA in the pathogenesis of Richter syndrome
Van Roosbroeck K., Bayraktar R., Calin S., Bloehdorn J., Dragomir M. P., Okubo K., Bertilaccio M. T. S., Zupo S., You M. J., Gaidano G., Rossi D., Chen S. S., Chiorazzi N., Thompson P. A., Ferrajoli A., Bertoni F., Stilgenbauer S., Keating M. J., Calin G. A.
Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia
Papakonstantinou N., Ntoufa S., Tsagiopoulou M., Moysiadis T., Bhoi S., Malousi A., Psomopoulos F., Mansouri L., Laidou S., Papazoglou D., Gounari M., Pasentsis K., Plevova K., Kuci-Emruli V., Duran-Ferrer M., Davis Z., Ek S., Rossi D., Gaidano G., Ritgen M., Oscier D., Stavroyianni N., Pospisilova S., Davi F., Ghia P., Hadzidimitriou A., Belessi C., Martin-Subero J. I., Pott C., Rosenquist R., Stamatopoulos K.
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies
Bergaggio E., Riganti C., Garaffo G., Vitale N., Mereu E., Bandini C., Pellegrino E., Pullano V., Omedè P., Todoerti K., Cascione L., Audrito V., Riccio A., Rossi A., Bertoni F., Deaglio S., Neri A., Palumbo A., Piva R.
Overview of non-coding mutations in chronic lymphocytic leukemia
Spina V., Rossi D.
Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach
Da Ros S., Aresu L., Ferraresso S., Zorzan E., Gaudio E., Bertoni F., Dacasto M., Giantin M.
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Aresu L., Ferraresso S., Marconato L., Cascione L., Napoli S., Gaudio E., Kwee I., Tarantelli C., Testa A., Maniaci C., Ciulli A., Hillmann P., Bohnacker T., Wymann M. P., Comazzi S., Milan M., Riondato F., Rovere G. D., Giantin M., Giannuzzi D., Bertoni F.
Liquid biopsy in tissue-born lymphomas
Spina V., Rossi D.
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
Tarantelli C., Zhang L., Curti E., Gaudio E., Spriano F., Priebe V., Cascione L., Arribas A. J., Zucca E., Rossi D., Stathis A., Bertoni F.
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents
Tarantelli C., Zhang L., Curti E., Gaudio E., Spriano F., Priebe V., Cascione L., Arribas A. J., Zucca E., Rossi D., Stathis A., Bertoni F.
Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors
Moysiadis T., Baliakas P., Rossi D., Catherwood M., Strefford J. C., Delgado J., Anagnostopoulos A., Belessi C., Stavroyianni N., Pospisilova S., Oscier D., Gaidano G., Campo E., Rosenquist R., Ghia P., Stamatopoulos K.
Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment
Condoluci A., Rossi D.
Genome-wide promoter methylation of hairy cell leukemia
Arribas A. J., Rinaldi A., Chiodin G., Kwee I., Mensah A. A., Cascione L., Rossi D., Kanduri M., Rosenquist R., Zucca E., Johnson P. W., Gaidano G., Oakes C. C., Bertoni F., Forconi F.
Genome-wide promoter methylation of hairy cell leukemia
Arribas A. J., Rinaldi A., Chiodin G., Kwee I., Mensah A. A., Cascione L., Rossi D., Kanduri M., Rosenquist R., Zucca E., Johnson P. W., Gaidano G., Oakes C. C., Bertoni F., Forconi F.
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Hicks S. W., Tarantelli C., Wilhem A., Gaudio E., Li M., Arribas A. J., Spriano F., Bordone R., Cascione L., Lai K. C., Qiu Q., Taborelli M., Rossi D., Stussi G., Zucca E., Stathis A., Sloss C. M., Bertoni F.
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Hicks S. W., Tarantelli C., Wilhem A., Gaudio E., Li M., Arribas A. J., Spriano F., Bordone R., Cascione L., Lai K. C., Qiu Q., Taborelli M., Rossi D., Stussi G., Zucca E., Stathis A., Sloss C. M., Bertoni F.
Reply to J. Wang et al
Kurtz D. M., Scherer F., Jin M. C., Soo J., Craig A. F. M., Esfahani M. S., Chabon J. J., Stehr H., Liu C. L., Tibshirani R., Maeda L. S., Gupta N. K., Khodadoust M. S., Advani R. H., Newman A. M., Dührsen U., Hüttmann A., Meignan M., Casasnovas O., Westin J. R., Roschewski M., Wilson W. H., Gaidano G., Rossi D., Diehn M., Alizadeh A. A.
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma
Heavican T. B., Bouska A., Yu J., Lone W., Amador C., Gong Q., Zhang W., Li Y., Dave B. J., Nairismägi M. L., Greiner T. C., Vose J., Weisenburger D. D., Lachel C., Wang C., Fu K., Stevens J. M., Lim S. T., Ong C. K., Gascoyne R. D., Missiaglia E., Lemonnier F., Haioun C., Hartmann S., Pedersen M. B., Laginestra M. A., Wilcox R. A., Teh B. T., Yoshida N., Ohshima K., Seto M., Rosenwald A., Ott G., Campo E., Rimsza L. M., Jaffe E. S., Braziel R. M., d'Amore F., Inghirami G., Bertoni F., de Leval L., Gaulard P., Staudt L. M., McKeithan T. W., Pileri S., Chan W. C., Iqbal J.
FBXW7 is a biologically validated cancer driver gene for CLL
Liquid biopsy in lymphoma
Rossi D., Spina V., Bruscaggin A., Gaidano G.
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Sasi B. K., Martines C., Xerxa E., Porro F., Kalkan H., Fazio R., Turkalj S., Bojnik E., Pyrzynska B., Stachura J., Zerrouqi A., Bobrowicz M., Winiarska M., Priebe V., Bertoni F., Mansouri L., Rosenquist R., Efremov D. G.
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Cascione L., Rinaldi A., Bruscaggin A., Tarantelli C., Arribas A. J., Kwee I., Pecciarini L., Mensah A. A., Spina V., Chung E. Y. L., di Bergamo L. T., Dirnhofer S., Tzankov A., Miranda R. N., Young K. H., Traverse-Glehen A., Gaidano G., Swerdlow S. H., Gascoyne R., Rabadan R., Ponzoni M., Bhagat G., Rossi D., Zucca E., Bertoni F.
Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Cascione L., Rinaldi A., Bruscaggin A., Tarantelli C., Arribas A. J., Kwee I., Pecciarini L., Mensah A. A., Spina V., Chung E. Y. L., di Bergamo L. T., Dirnhofer S., Tzankov A., Miranda R. N., Young K. H., Traverse-Glehen A., Gaidano G., Swerdlow S. H., Gascoyne R., Rabadan R., Ponzoni M., Bhagat G., Rossi D., Zucca E., Bertoni F.
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified
Laginestra M. A., Cascione L., Motta G., Fuligni F., Agostinelli C., Rossi M., Sapienza M. R., Righi S., Broccoli A., Indio V., Melle F., Tabanelli V., Calleri A., Novero D., Facchetti F., Inghirami G., Sabattini E., Bertoni F., Pileri S. A.
The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas
Condoluci A., Rossi D.
Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies
Bertoni F., Stathis A.
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Spriano F., Chung E. Y. L., Gaudio E., Tarantelli C., Cascione L., Napoli S., Jessen K., Carrassa L., Priebe V., Sartori G., Graham G., Selvanathan S. P., Cavalli A., Rinaldi A., Kwee I., Testoni M., Genini D., Ye B. H., Zucca E., Stathis A., Lannutti B., Toretsky J. A., Bertoni F.
Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models
Astorgues-Xerri L., Vázquez R., Odore E., Rezai K., Kahatt C., Mackenzie S., Bekradda M., Coudé M. M., Dombret H., Gardin C., Lokiec F., Raymond E., Noel K., Cvitkovic E., Herait P., Bertoni F., Riveiro M. E.
Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14)
Ghilardi G., Stussi G., Mazzucchelli L., Röcken C., Rossi D., Gerber B.
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
Kurtz D. M., Esfahani M. S., Scherer F., Soo J., Jin M. C., Liu C. L., Newman A. M., Dührsen U., Hüttmann A., Casasnovas O., Westin J. R., Ritgen M., Böttcher S., Langerak A. W., Roschewski M., Wilson W. H., Gaidano G., Rossi D., Bahlo J., Hallek M., Tibshirani R., Diehn M., Alizadeh A. A.
Primary central nervous system lymphoma: Novel precision therapies
Mondello P., Mian M., Bertoni F.
Quest of biomarkers for venetoclax-treated CLL
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas
Spriano F., Tarantelli C., Gaudio E., Gerlach M. M., Priebe V., Cascione L., Bernasconi E., Targa A., Mascia M., Dirnhofer S., Stathis A., Zucca E., Bertoni F.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Diop F., Moia R., Favini C., Spaccarotella E., De Paoli L., Bruscaggin A., Spina V., Terzi-di-Bergamo L., Arruga F., Tarantelli C., Deambrogi C., Rasi S., Adhinaveni R., Patriarca A., Favini S., Sagiraju S., Jabangwe C., Kodipad A. A., Peroni D., Mauro F. R., Giudice I. D., Forconi F., Cortelezzi A., Zaja F., Bomben R., Rossi F. M., Visco C., Chiarenza A., Rigolin G. M., Marasca R., Coscia M., Perbellini O., Tedeschi A., Laurenti L., Motta M., Donaldson D., Weir P., Mills K., Thornton P., Lawless S., Bertoni F., Poeta G. D., Cuneo A., Follenzi A., Gattei V., Boldorini R. L., Catherwood M., Deaglio S., Foà R., Gaidano G., Rossi D.
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia
Diop F., Moia R., Favini C., Spaccarotella E., De Paoli L., Bruscaggin A., Spina V., Terzi-di-Bergamo L., Arruga F., Tarantelli C., Deambrogi C., Rasi S., Adhinaveni R., Patriarca A., Favini S., Sagiraju S., Jabangwe C., Kodipad A. A., Peroni D., Mauro F. R., Giudice I. D., Forconi F., Cortelezzi A., Zaja F., Bomben R., Rossi F. M., Visco C., Chiarenza A., Rigolin G. M., Marasca R., Coscia M., Perbellini O., Tedeschi A., Laurenti L., Motta M., Donaldson D., Weir P., Mills K., Thornton P., Lawless S., Bertoni F., Poeta G. D., Cuneo A., Follenzi A., Gattei V., Boldorini R. L., Catherwood M., Deaglio S., Foà R., Gaidano G., Rossi D.
Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden
Schwotzer R., Manz M. G., Pederiva S., Waibel C., Caspar C., Lerch E., Flammer A. J., Brouwers S., Seeger H., Heimgartner R., Fehr T., Rossi D., Bianchi E., Stüssi G., Ghilardi G., Gerber B.
STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma
Mondello P., Cuzzocrea S., Arrigo C., Pitini V., Mian M., Bertoni F.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Ferrero S., Rossi D., Rinaldi A., Bruscaggin A., Spina V., Eskelund C. W., Evangelista A., Moia R., Kwee I., Dahl C., Di Rocco A., Stefoni V., Diop F., Favini C., Ghione P., Mahmoud A. M., Schipani M., Kolstad A., Barbero D., Novero D., Paulli M., Zamò A., Jerkeman M., da Silva M. G., Santoro A., Molinari A., Ferreri A., Grønbæk K., Piccin A., Cortelazzo S., Bertoni F., Ladetto M., Gaidano G.
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Ferrero S., Rossi D., Rinaldi A., Bruscaggin A., Spina V., Eskelund C. W., Evangelista A., Moia R., Kwee I., Dahl C., Di Rocco A., Stefoni V., Diop F., Favini C., Ghione P., Mahmoud A. M., Schipani M., Kolstad A., Barbero D., Novero D., Paulli M., Zamò A., Jerkeman M., da Silva M. G., Santoro A., Molinari A., Ferreri A., Grønbæk K., Piccin A., Cortelazzo S., Bertoni F., Ladetto M., Gaidano G.
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified
Laginestra M. A., Cascione L., Motta G., Fuligni F., Agostinelli C., Rossi M., Sapienza M. R., Righi S., Broccoli A., Indio V., Melle F., Tabanelli V., Calleri A., Novero D., Facchetti F., Inghirami G., Sabattini E., Bertoni F., Pileri S. A.
Targeting PML in triple negative breast cancer elicits growth suppression and senescence
Arreal L., Piva M., Fernández S., Revandkar A., Schaub-Clerigué A., Villanueva J., Zabala-Letona A., Pujana M., Astobiza I., Cortazar A. R., Hermanova I., Bozal-Basterra L., Arruabarrena-Aristorena A., Crespo J. R., Valcarcel-Jimenez L., Zúñiga-García P., Canals F., Torrano V., Barrio R., Sutherland J. D., Alimonti A., Martin-Martin N., Carracedo A.
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
Cohen J. A., Rossi F. M., Zucchetto A., Bomben R., Terzi-di-Bergamo L., Rabe K. G., Degan M., Steffan A., Polesel J., Santinelli E., Innocenti I., Cutrona G., D'Arena G., Pozzato G., Zaja F., Chiarenza A., Rossi D., Di Raimondo F., Laurenti L., Gentile M., Morabito F., Neri A., Ferrarini M., Fegan C. D., Pepper C. J., Del Poeta G., Parikh S. A., Kay N. E., Gattei V.
The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
Rødland G. E., Melhus K., Generalov R., Gilani S., Bertoni F., Dahle J., Syljuåsen R. G., Patzke S.
The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA
Rossi D., Kurtz D. M., Roschewski M., Cavalli F., Zucca E., Wilson W. H.
TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss
Pietrzak K., Kuzyakiv R., Simon R., Bolis M., Bär D., Aprigliano R., Theurillat J. P., Sauter G., Santoro R.
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C., Lupia A., Stathis A., Bertoni F.
Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer
Ricci F., Guffanti F., Affatato R., Brunelli L., Roberta P., Fruscio R., Perego P., Bani M. R., Chiorino G., Rinaldi A., Bertoni F., Fratelli M., Damia G.
HMGA1-pseudogene7 transgenic mice develop B cell lymphomas
De Martino M., De Biase D., Forzati F., Credendino S. C., Palma G., Barbieri A., Arra C., Paciello O., Gaudio E., Ponzoni M., De Vita G., Chieffi P., Bertoni F., Fusco A., Esposito F.
Marginal Zone Lymphomas
Bertoni F., Rossi D., Raderer M., Zucca E.
Marginal Zone Lymphomas
Bertoni F., Rossi D., Raderer M., Zucca E.
Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
Spanò V., Rocca R., Barreca M., Giallombardo D., Montalbano A., Carbone A., Raimondi M. V., Gaudio E., Bortolozzi R., Bai R., Tassone P., Alcaro S., Hamel E., Viola G., Bertoni F., Barraja P.
Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
Spanò V., Rocca R., Barreca M., Giallombardo D., Montalbano A., Carbone A., Raimondi M. V., Gaudio E., Bortolozzi R., Bai R., Tassone P., Alcaro S., Hamel E., Viola G., Bertoni F., Barraja P.
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis
Guccini I., Revandkar A., D'Ambrosio M., Colucci M., Pasquini E., Mosole S., Troiani M., Brina D., Sheibani-Tezerji R., Elia A. R., Rinaldi A., Pernigoni N., Rüschoff J. H., Dettwiler S., De Marzo A. M., Antonarakis E. S., Borrelli C., Moor A. E., Garcia-Escudero R., Alajati A., Attanasio G., Losa M., Moch H., Wild P., Egger G., Alimonti A.
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia
Klintman J., Appleby N., Stamatopoulos B., Ridout K., Eyre T. A., Robbe P., Pascua L. L., Knight S. J. L., Dreau H., Cabes M., Popitsch N., Ehinger M., Martín-Subero J. I., Campo E., Månsson R., Rossi D., Taylor J. C., Vavoulis D. V., Schuh A.
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Barreca M., Spanò V., Montalbano A., Cueto M., Díaz Marrero A. R., Deniz I., Erdoğan A., Lukić Bilela L., Moulin C., Taffin-de-Givenchy E., Spriano F., Perale G., Mehiri M., Rotter A., P. Thomas O, Barraja P., Gaudêncio S. P., Bertoni F.
DNA Copy Number Changes in Diffuse Large B Cell Lymphomas
Cascione L., Aresu L., Baudis M., Bertoni F.
Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma
Aresu L., Agnoli C., Nicoletti A., Fanelli A., Martini V., Bertoni F., Marconato L.
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
Paschalis A., Welti J., Neeb A. J., Yuan W., Figueiredo I., Pereira R., Ferreira A., Riisnaes R., Rodrigues D. N., Jiménez-Vacas J. M., Kim S., Uo T., Micco P. D., Tumber A., Islam M. S., Moesser M. A., Abboud M., Kawamura A., Gurel B., Christova R., Gil V. S., Buroni L., Crespo M., Miranda S., Lambros M. B., Carreira S., Tunariu N., Alimonti A., Al-Lazikani B., Schofield C. J., Plymate S. R., Sharp A., de Bono J. S.
Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ(1) receptor affinity, antitumor and analgesic activity
Kopp N., Civenni G., Marson D., Laurini E., Pricl S., Catapano C. V., Humpf H. U., Almansa C., Nieto F. R., Schepmann D., Wünsch B.
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Alig S., Macaulay C. W., Kurtz D. M., Dührsen U., Hüttmann A., Schmitz C., Jin M. C., Sworder B. J., Garofalo A., Shahrokh Esfahani M., Nabet B. Y., Soo J., Scherer F., Craig A. F. M., Casasnovas O., Westin J. R., Gaidano G., Rossi D., Roschewski M., Wilson W. H., Meignan M., Diehn M., Alizadeh A. A.
Exon-Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
Munz N., Cascione L., Parmigiani L., Tarantelli C., Rinaldi A., Cmiljanovic N., Cmiljanovic V., Giugno R., Bertoni F., Napoli S.
Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma
Pietrobono S., Gaudio E., Gagliardi S., Zitani M., Carrassa L., Migliorini F., Petricci E., Manetti F., Makukhin N., Bond A. G., Paradise B. D., Ciulli A., Fernandez-Zapico M. E., Bertoni F., Stecca B.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
Morabito F., Del Poeta G., Mauro F. R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Bossio S., Varettoni M., Murru R., Chiarenza A., Visentin A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Recchia A. G., Rossi F. M., Zucchetto A., Al-Janazreh H., Martino E. A., Vigna E., Tripepi G., D'Arrigo G., Galimberti S., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Neri A., Fronza G., Cutrona G., Jaksic O., Olivieri J., Rossi D., Di Raimondo F., Cuneo A., Gaidano G., Polliack A., Trentin L., Foà R., Ferrarini M., Gattei V., Gentile M.
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors
Mensah A. A., Spriano F., Sartori G., Priebe V., Cascione L., Gaudio E., Tarantelli C., Civanelli E., Aresu L., Rinaldi A., Damia G., Lovati E., Zucca E., Stathis A., Pietra C., Bertoni F.
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
El Tekle G., Bernasocchi T., Unni A. M., Bertoni F., Rossi D., Rubin M. A., Theurillat J. P.
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
El Tekle G., Bernasocchi T., Unni A. M., Bertoni F., Rossi D., Rubin M. A., Theurillat J. P.
Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
El Tekle G., Bernasocchi T., Unni A. M., Bertoni F., Rossi D., Rubin M. A., Theurillat J. P.
Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma
Fangazio M., Ladewig E., Gomez K., Garcia-Ibanez L., Kumar R., Teruya-Feldstein J., Rossi D., Filip I., Pan-Hammarström Q., Inghirami G., Boldorini R., Ott G., Staiger A. M., Chapuy B., Gaidano G., Bhagat G., Basso K., Rabadan R., Pasqualucci L., Dalla-Favera R.
HMGA1 induces EZH2 overexpression in human B-cell lymphomas
De Martino M., Nicolau-Neto P., Ribeiro Pinto L. F., Traverse-Glehen A., Bachy E., Gigantino V., De Cecio R., Bertoni F., Chieffi P., Fusco A., Esposito F.
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma
Napoli S., Cascione L., Rinaldi A., Spriano F., Guidetti F., Zhang F., Cacciapuoti M. T., Mensah A. A., Sartori G., Munz N., Forcato M., Bicciato S., Chiappella A., Ghione P., Elemento O., Cerchietti L., Inghirami G., Bertoni F.
Inflammatory metabolic profile of South African patients with prostate cancer
Cacciatore S., Wium M., Licari C., Ajayi-Smith A., Masieri L., Anderson C., Salukazana A. S., Kaestner L., Carini M., Carbone G. M., Catapano C. V., Loda M., Libermann T. A., Zerbini L. F.
Inflammatory metabolic profile of South African patients with prostate cancer
Cacciatore S., Wium M., Licari C., Ajayi-Smith A., Masieri L., Anderson C., Salukazana A. S., Kaestner L., Carini M., Carbone G. M., Catapano C. V., Loda M., Libermann T. A., Zerbini L. F.
Microsatellite instability in gastric MALT lymphomas and other associated neoplasms
Furlan D., Bertoni F., Cerutti R., Taborelli M., Pinotti G., Roggero E., Cavalli F., Bonato M., Zucca E., Capella C.
CDCP1 initiates tumorigenesis and cooperates with PTEN loss to promote senescence evasion and prostate cancer progression
Alajati A, Chen J, Alimonti A
MALT lymphomas: pathogenesis can drive treatment
Bertoni F., Coiffier B., Salles G., Stathis A., Traverse-Glehen A., Thieblemont C., Zucca E.
Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma
Bertoni F., Bosshard G., Roggero E., Ceresa E., Cavalli F., Zucca E.
Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip
Migliore A., Martin L. S., Alimonti A., Valente C., Tormenta S.
A man with a deltoid swelling and paraneoplastic erythrocytosis: case report
Alimonti A., Di Cosimo S., Maccallini V., Ferretti G., Pavese I., Satta F., Di Palma M., Vecchione A.
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene
Carbone G. M., McGuffie E., Napoli S., Flanagan C. E., Dembech C., Negri U., Arcamone F., Capobianco M. L., Catapano C. V.
DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene
Carbone G. M., McGuffie E., Napoli S., Flanagan C. E., Dembech C., Negri U., Arcamone F., Capobianco M. L., Catapano C. V.
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells
Carbone G. M., Napoli S., Valentini A., Cavalli F., Watson D. K., Catapano C. V.
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells
Carbone G. M., Napoli S., Valentini A., Cavalli F., Watson D. K., Catapano C. V.
Neomycin improves cationic lipid-mediated transfection of DNA in human cells
Napoli S., Carbone G. M., Catapano C. V., Shaw N., Arya D. P.
Neomycin improves cationic lipid-mediated transfection of DNA in human cells
Napoli S., Carbone G. M., Catapano C. V., Shaw N., Arya D. P.
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., Poretti G., Gaidano G., Calabrese G., Martinelli G., Baldini L., Pruneri G., Capella C., Zucca E., Cotter F. E., Cigudosa J. C., Catapano C. V., Tibiletti M. G., Bertoni F.
Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
Rinaldi A., Kwee I., Taborelli M., Largo C., Uccella S., Martin V., Poretti G., Gaidano G., Calabrese G., Martinelli G., Baldini L., Pruneri G., Capella C., Zucca E., Cotter F. E., Cigudosa J. C., Catapano C. V., Tibiletti M. G., Bertoni F.
Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells
Napoli S., Negri U., Arcamone F., Capobianco M. L., Carbone G. M., Catapano C. V.
Growth inhibition and apoptosis induced by daunomycin-conjugated triplex-forming oligonucleotides targeting the c-myc gene in prostate cancer cells
Napoli S., Negri U., Arcamone F., Capobianco M. L., Carbone G. M., Catapano C. V.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy
Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I., Nur-e-Alam M., Bergant J., Bertoni F., Carbone G. M., Rohr J., Catapano C. V.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy
Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I., Nur-e-Alam M., Bergant J., Bertoni F., Carbone G. M., Rohr J., Catapano C. V.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy
Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I., Nur-e-Alam M., Bergant J., Bertoni F., Carbone G. M., Rohr J., Catapano C. V.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy
Albertini V., Jain A., Vignati S., Napoli S., Rinaldi A., Kwee I., Nur-e-Alam M., Bergant J., Bertoni F., Carbone G. M., Rohr J., Catapano C. V.
Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system
Genini D., Catapano C. V.
Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity
Genini D., Catapano C. V.
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Lacrima K., Rinaldi A., Vignati S., Martin V., Tibiletti M. G., Gaidano G., Catapano C. V., Bertoni F.
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Lacrima K., Rinaldi A., Vignati S., Martin V., Tibiletti M. G., Gaidano G., Catapano C. V., Bertoni F.
Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer
Cangemi R., Mensah A., Albertini V., Jain A., Mello-Grand M., Chiorino G., Catapano C. V., Carbone G. M.
Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer
Cangemi R., Mensah A., Albertini V., Jain A., Mello-Grand M., Chiorino G., Catapano C. V., Carbone G. M.
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis
Genini D., Carbone G. M., Catapano C. V.
Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis
Genini D., Carbone G. M., Catapano C. V.
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells
Napoli S., Pastori C., Magistri M., Carbone G. M., Catapano C. V.
Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells
Napoli S., Pastori C., Magistri M., Carbone G. M., Catapano C. V.
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas
Scandurra M., Rossi D., Deambrogi C., Rancoita P. M., Chigrinova E., Mian M., Cerri M., Rasi S., Sozzi E., Forconi F., Ponzoni M., Moreno S. M., Piris M. A., Inghirami G., Zucca E., Gattei V., Rinaldi A., Kwee I., Gaidano G., Bertoni F.
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas
Scandurra M., Rossi D., Deambrogi C., Rancoita P. M., Chigrinova E., Mian M., Cerri M., Rasi S., Sozzi E., Forconi F., Ponzoni M., Moreno S. M., Piris M. A., Inghirami G., Zucca E., Gattei V., Rinaldi A., Kwee I., Gaidano G., Bertoni F.
Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells
Jain A., Magistri M., Napoli S., Carbone G. M., Catapano C. V.
Mechanisms of triplex DNA-mediated inhibition of transcription initiation in cells
Jain A., Magistri M., Napoli S., Carbone G. M., Catapano C. V.
A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models
Malek A., Catapano C. V., Czubayko F., Aigner A.
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer
Kunderfranco P., Mello-Grand M., Cangemi R., Pellini S., Mensah A., Albertini V., Malek A., Chiorino G., Catapano C. V., Carbone G. M.
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer
Kunderfranco P., Mello-Grand M., Cangemi R., Pellini S., Mensah A., Albertini V., Malek A., Chiorino G., Catapano C. V., Carbone G. M.
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
Rinaldi A., Mian M., Kwee I., Rossi D., Deambrogi C., Mensah A. A., Forconi F., Spina V., Cencini E., Drandi D., Ladetto M., Santachiara R., Marasca R., Gattei V., Cavalli F., Zucca E., Gaidano G., Bertoni F.
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia
Rinaldi A., Mian M., Kwee I., Rossi D., Deambrogi C., Mensah A. A., Forconi F., Spina V., Cencini E., Drandi D., Ladetto M., Santachiara R., Marasca R., Gattei V., Cavalli F., Zucca E., Gaidano G., Bertoni F.
Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma
Kwee I., Capello D., Rinaldi A., Rancoita P. M., Bhagat G., Greiner T. C., Spina M., Gloghini A., Chan W. C., Paulli M., Zucca E., Tirelli U., Carbone A., Gaidano G., Bertoni F.
Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma
Kwee I., Capello D., Rinaldi A., Rancoita P. M., Bhagat G., Greiner T. C., Spina M., Gloghini A., Chan W. C., Paulli M., Zucca E., Tirelli U., Carbone A., Gaidano G., Bertoni F.
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array
Kwee I., Rinaldi A., Rancoita P., Rossi D., Capello D., Forconi F., Giuliani N., Piva R., Inghirami G., Gaidano G., Zucca E., Bertoni F.
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array
Kwee I., Rinaldi A., Rancoita P., Rossi D., Capello D., Forconi F., Giuliani N., Piva R., Inghirami G., Gaidano G., Zucca E., Bertoni F.
PTEN breast cancer susceptibility: a matter of dose
ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features
Albino D., Longoni N., Curti L., Mello-Grand M., Pinton S., Civenni G., Thalmann G., D'Ambrosio G., Sarti M., Sessa F., Chiorino G., Catapano C. V., Carbone G. M.
ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features
Albino D., Longoni N., Curti L., Mello-Grand M., Pinton S., Civenni G., Thalmann G., D'Ambrosio G., Sarti M., Sessa F., Chiorino G., Catapano C. V., Carbone G. M.
Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer
Malek A., Nunez L. E., Magistri M., Brambilla L., Jovic S., Carbone G. M., Moris F., Catapano C. V.
Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer
Malek A., Nunez L. E., Magistri M., Brambilla L., Jovic S., Carbone G. M., Moris F., Catapano C. V.
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression
Longoni N., Kunderfranco P., Pellini S., Albino D., Mello-Grand M., Pinton S., D'Ambrosio G., Sarti M., Sessa F., Chiorino G., Catapano C. V., Carbone G. M.
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression
Longoni N., Kunderfranco P., Pellini S., Albino D., Mello-Grand M., Pinton S., D'Ambrosio G., Sarti M., Sessa F., Chiorino G., Catapano C. V., Carbone G. M.
Transcriptional and Non-Transcriptional Functions of PPARbeta/delta in Non-Small Cell Lung Cancer
Genini D., Garcia-Escudero R., Carbone G. M., Catapano C. V.
Transcriptional and Non-Transcriptional Functions of PPARbeta/delta in Non-Small Cell Lung Cancer
Genini D., Garcia-Escudero R., Carbone G. M., Catapano C. V.
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH
Mian M., Rinaldi A., Mensah A. A., Rossi D., Ladetto M., Forconi F., Marasca R., Uhr M., Stussi G., Kwee I., Cavalli F., Gaidano G., Zucca E., Bertoni F.
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH
Mian M., Rinaldi A., Mensah A. A., Rossi D., Ladetto M., Forconi F., Marasca R., Uhr M., Stussi G., Kwee I., Cavalli F., Gaidano G., Zucca E., Bertoni F.
The changing paradigm of chronic lymphocytic leukemia management
Lobetti-Bodoni C., Bertoni F., Stussi G., Cavalli F., Zucca E.
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression
Longoni N., Sarti M., Albino D., Civenni G., Malek A., Ortelli E., Pinton S., Mello-Grand M., Ostano P., D'Ambrosio G., Sessa F., Garcia-Escudero R., Thalmann G. N., Chiorino G., Catapano C. V., Carbone G. M.
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-kappaB and drives prostate cancer progression
Longoni N., Sarti M., Albino D., Civenni G., Malek A., Ortelli E., Pinton S., Mello-Grand M., Ostano P., D'Ambrosio G., Sessa F., Garcia-Escudero R., Thalmann G. N., Chiorino G., Catapano C. V., Carbone G. M.
Differential expression of testin and survivin in breast cancer subtypes
Sarti M., Pinton S., Limoni C., Carbone G. M., Pagani O., Cavalli F., Catapano C. V.
Differential expression of testin and survivin in breast cancer subtypes
Sarti M., Pinton S., Limoni C., Carbone G. M., Pagani O., Cavalli F., Catapano C. V.
Toward new treatments for mantle-cell lymphoma?
Zucca E., Bertoni F.
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Rinaldi A., Mensah A. A., Kwee I., Forconi F., Orlandi E. M., Lucioni M., Gattei V., Marasca R., Berger F., Cogliatti S., Cavalli F., Zucca E., Gaidano G., Rossi D., Bertoni F.
Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma
Rinaldi A., Mensah A. A., Kwee I., Forconi F., Orlandi E. M., Lucioni M., Gattei V., Marasca R., Berger F., Cogliatti S., Cavalli F., Zucca E., Gaidano G., Rossi D., Bertoni F.
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Chigrinova E., Rinaldi A., Kwee I., Rossi D., Rancoita P. M., Strefford J. C., Oscier D., Stamatopoulos K., Papadaki T., Berger F., Young K. H., Murray F., Rosenquist R., Greiner T. C., Chan W. C., Orlandi E. M., Lucioni M., Marasca R., Inghirami G., Ladetto M., Forconi F., Cogliatti S., Votavova H., Swerdlow S. H., Stilgenbauer S., Piris M. A., Matolcsy A., Spagnolo D., Nikitin E., Zamo A., Gattei V., Bhagat G., Ott G., Zucca E., Gaidano G., Bertoni F.
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
Chigrinova E., Rinaldi A., Kwee I., Rossi D., Rancoita P. M., Strefford J. C., Oscier D., Stamatopoulos K., Papadaki T., Berger F., Young K. H., Murray F., Rosenquist R., Greiner T. C., Chan W. C., Orlandi E. M., Lucioni M., Marasca R., Inghirami G., Ladetto M., Forconi F., Cogliatti S., Votavova H., Swerdlow S. H., Stilgenbauer S., Piris M. A., Matolcsy A., Spagnolo D., Nikitin E., Zamo A., Gattei V., Bhagat G., Ott G., Zucca E., Gaidano G., Bertoni F.
RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer
Civenni G., Malek A., Albino D., Garcia-Escudero R., Napoli S., Di Marco S., Pinton S., Sarti M., Carbone G. M., Catapano C. V.
RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer
Civenni G., Malek A., Albino D., Garcia-Escudero R., Napoli S., Di Marco S., Pinton S., Sarti M., Carbone G. M., Catapano C. V.
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas
Mian M., Kwee I., Rinaldi A., Ponzoni M., Bhagat G., Rossi D., Arcaini L., Gascoyne R. D., Mollejo M., Baldini L., Thieblemont C., Gaidano G., Zucca E., Bertoni F.
Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas
Mian M., Kwee I., Rinaldi A., Ponzoni M., Bhagat G., Rossi D., Arcaini L., Gascoyne R. D., Mollejo M., Baldini L., Thieblemont C., Gaidano G., Zucca E., Bertoni F.
Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type
Thieblemont C., Bertoni F., Copie-Bergman C., Ferreri A. J., Ponzoni M.
Circulating miRNA markers show promise as new prognosticators for multiple myeloma
Rocci A., Hofmeister C. C., Geyer S., Stiff A., Gambella M., Cascione L., Guan J., Benson D. M., Efebera Y. A., Talabere T., Dirisala V., Smith E. M., Omede P., Isaia G., De Luca L., Rossi D., Gentili S., Uccello G., Consiglio J., Ria R., Benevolo G., Bringhen S., Callea V., Weiss B., Ferro A., Magarotto V., Alder H., Byrd J. C., Boccadoro M., Marcucci G., Palumbo A., Pichiorri F.
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Toso A., Revandkar A., Di Mitri D., Guccini I., Proietti M., Sarti M., Pinton S., Zhang J., Kalathur M., Civenni G., Jarrossay D., Montani E., Marini C., Garcia-Escudero R., Scanziani E., Grassi F., Pandolfi P. P., Catapano C. V., Alimonti A.
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Toso A., Revandkar A., Di Mitri D., Guccini I., Proietti M., Sarti M., Pinton S., Zhang J., Kalathur M., Civenni G., Jarrossay D., Montani E., Marini C., Garcia-Escudero R., Scanziani E., Grassi F., Pandolfi P. P., Catapano C. V., Alimonti A.
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Toso A., Revandkar A., Di Mitri D., Guccini I., Proietti M., Sarti M., Pinton S., Zhang J., Kalathur M., Civenni G., Jarrossay D., Montani E., Marini C., Garcia-Escudero R., Scanziani E., Grassi F., Pandolfi P. P., Catapano C. V., Alimonti A.
The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma
Piva R., Deaglio S., Fama R., Buonincontri R., Scarfo I., Bruscaggin A., Mereu E., Serra S., Spina V., Brusa D., Garaffo G., Monti S., Dal Bo M., Marasca R., Arcaini L., Neri A., Gattei V., Paulli M., Tiacci E., Bertoni F., Pileri S. A., Foa R., Inghirami G., Gaidano G., Rossi D.
The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma
Piva R., Deaglio S., Fama R., Buonincontri R., Scarfo I., Bruscaggin A., Mereu E., Serra S., Spina V., Brusa D., Garaffo G., Monti S., Dal Bo M., Marasca R., Arcaini L., Neri A., Gattei V., Paulli M., Tiacci E., Bertoni F., Pileri S. A., Foa R., Inghirami G., Gaidano G., Rossi D.
Marine sponge Cribrochalina vasculum compounds activate intrinsic apoptotic signaling and inhibit growth factor signaling cascades in non-small cell lung carcinoma
Zovko A., Viktorsson K., Haag P., Kovalerchick D., Farnegardh K., Alimonti A., Ilan M., Carmeli S., Lewensohn R.
Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells
Roos M., Rebhan M. A., Lucic M., Pavlicek D., Pradere U., Towbin H., Civenni G., Catapano C. V., Hall J.
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
Arribas A. J., Rinaldi A., Mensah A. A., Kwee I., Cascione L., Robles E. F., Martinez-Climent J. A., Oscier D., Arcaini L., Baldini L., Marasca R., Thieblemont C., Briere J., Forconi F., Zamo A., Bonifacio M., Mollejo M., Facchetti F., Dirnhofer S., Ponzoni M., Bhagat G., Piris M. A., Gaidano G., Zucca E., Rossi D., Bertoni F.
DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features
Arribas A. J., Rinaldi A., Mensah A. A., Kwee I., Cascione L., Robles E. F., Martinez-Climent J. A., Oscier D., Arcaini L., Baldini L., Marasca R., Thieblemont C., Briere J., Forconi F., Zamo A., Bonifacio M., Mollejo M., Facchetti F., Dirnhofer S., Ponzoni M., Bhagat G., Piris M. A., Gaidano G., Zucca E., Rossi D., Bertoni F.
Association of mitochondrial deoxyribonucleic acid mutation with polymorphism in CYP2E1 gene in oral carcinogenesis
Pandey R., Mehrotra D., Catapano C., Choubey V., Sarin R., Mahdi A. A., Singh S.
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
Brambilla L., Genini D., Laurini E., Merulla J., Perez L., Fermeglia M., Carbone G. M., Pricl S., Catapano C. V.
Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
Brambilla L., Genini D., Laurini E., Merulla J., Perez L., Fermeglia M., Carbone G. M., Pricl S., Catapano C. V.
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma
Crescenzo R., Abate F., Lasorsa E., Tabbo F., Gaudiano M., Chiesa N., Di Giacomo F., Spaccarotella E., Barbarossa L., Ercole E., Todaro M., Boi M., Acquaviva A., Ficarra E., Novero D., Rinaldi A., Tousseyn T., Rosenwald A., Kenner L., Cerroni L., Tzankov A., Ponzoni M., Paulli M., Weisenburger D., Chan W. C., Iqbal J., Piris M. A., Zamo A., Ciardullo C., Rossi D., Gaidano G., Pileri S., Tiacci E., Falini B., Shultz L. D., Mevellec L., Vialard J. E., Piva R., Bertoni F., Rabadan R., Inghirami G., European T-Cell Lymphoma Study Group T. Cell Project Prospective Collection of Data in Patients with Peripheral T. Cell Lymphoma, the Airc xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma
Crescenzo R., Abate F., Lasorsa E., Tabbo F., Gaudiano M., Chiesa N., Di Giacomo F., Spaccarotella E., Barbarossa L., Ercole E., Todaro M., Boi M., Acquaviva A., Ficarra E., Novero D., Rinaldi A., Tousseyn T., Rosenwald A., Kenner L., Cerroni L., Tzankov A., Ponzoni M., Paulli M., Weisenburger D., Chan W. C., Iqbal J., Piris M. A., Zamo A., Ciardullo C., Rossi D., Gaidano G., Pileri S., Tiacci E., Falini B., Shultz L. D., Mevellec L., Vialard J. E., Piva R., Bertoni F., Rabadan R., Inghirami G., European T-Cell Lymphoma Study Group T. Cell Project Prospective Collection of Data in Patients with Peripheral T. Cell Lymphoma, the Airc xMille Consortium Genetics-Driven Targeted Management of Lymphoid Malignancies
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C., Bertoni F., Alimonti A.
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C., Bertoni F., Alimonti A.
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C., Bertoni F., Alimonti A.
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C., Bertoni F., Alimonti A.
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Alajati A., Guccini I., Pinton S., Garcia-Escudero R., Bernasocchi T., Sarti M., Montani E., Rinaldi A., Montemurro F., Catapano C., Bertoni F., Alimonti A.
Enhancing chemotherapy efficacy by reprogramming the senescence-associated secretory phenotype of prostate tumors: A way to reactivate the antitumor immunity
Toso A., Di Mitri D., Alimonti A.
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Di Mitri D., Toso A., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours
Kalathur M., Toso A., Chen J., Revandkar A., Danzer-Baltzer C., Guccini I., Alajati A., Sarti M., Pinton S., Brambilla L., Di Mitri D., Carbone G., Garcia-Escudero R., Padova A., Magnoni L., Tarditi A., Maccari L., Malusa F., Kalathur R. K., A. Pinna L, Cozza G., Ruzzene M., Delaleu N., Catapano C. V., Frew I. J., Alimonti A.
Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by Integrative Modeling
Sgrignani J., Olsson S., Ekonomiuk D., Genini D., Krause R., Catapano C. V., Cavalli A.
Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors
Di Mitri D., Toso A., Alimonti A.
Non-Cell-Autonomous Regulation of Cellular Senescence in Cancer
Di Mitri D., Alimonti A.
Sjogren's syndrome patients with ectopic germinal centers present with a distinct salivary proteome
Delaleu N., Mydel P., Brun J. G., Jonsson M. V., Alimonti A., Jonsson R.
Splenic marginal zone lymphoma: from genetics to management
Arcaini L., Rossi D., Paulli M.
The clinical implications of gene mutations in chronic lymphocytic leukaemia
Rossi D., Gaidano G.
Venetoclax: a new weapon to treat high-risk CLL
Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer
Albino D., Civenni G., Dallavalle C., Roos M., Jahns H., Curti L., Rossi S., Pinton S., D'Ambrosio G., Sessa F., Hall J., Catapano C. V., Carbone G. M.
Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer
Albino D., Civenni G., Dallavalle C., Roos M., Jahns H., Curti L., Rossi S., Pinton S., D'Ambrosio G., Sessa F., Hall J., Catapano C. V., Carbone G. M.
TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer
Groner A. C., Cato L., de Tribolet-Hardy J., Bernasocchi T., Janouskova H., Melchers D., Houtman R., Cato A. C. B., Tschopp P., Gu L., Corsinotti A., Zhong Q., Fankhauser C., Fritz C., Poyet C., Wagner U., Guo T., Aebersold R., Garraway L. A., Wild P. J., Theurillat J. P., Brown M.
Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells
Rabi T., Catapano C. V.
The genetics of nodal marginal zone lymphoma
Spina V., Khiabanian H., Messina M., Monti S., Cascione L., Bruscaggin A., Spaccarotella E., Holmes A. B., Arcaini L., Lucioni M., Tabbo F., Zairis S., Diop F., Cerri M., Chiaretti S., Marasca R., Ponzoni M., Deaglio S., Ramponi A., Tiacci E., Pasqualucci L., Paulli M., Falini B., Inghirami G., Bertoni F., Foa R., Rabadan R., Gaidano G., Rossi D.
The genetics of nodal marginal zone lymphoma
Spina V., Khiabanian H., Messina M., Monti S., Cascione L., Bruscaggin A., Spaccarotella E., Holmes A. B., Arcaini L., Lucioni M., Tabbo F., Zairis S., Diop F., Cerri M., Chiaretti S., Marasca R., Ponzoni M., Deaglio S., Ramponi A., Tiacci E., Pasqualucci L., Paulli M., Falini B., Inghirami G., Bertoni F., Foa R., Rabadan R., Gaidano G., Rossi D.
Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
Gomes A. L., Teijeiro A., Buren S., Tummala K. S., Yilmaz M., Waisman A., Theurillat J. P., Perna C., Djouder N.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma
Gaudio E., Tarantelli C., Ponzoni M., Odore E., Rezai K., Bernasconi E., Cascione L., Rinaldi A., Stathis A., Riveiro E., Cvitkovic E., Zucca E., Bertoni F.
NF-kappaB deregulation in splenic marginal zone lymphoma
Spina V., Rossi D.
A Small-Molecule Inhibitor of Lin28
Roos M., Pradere U., Ngondo R. P., Behera A., Allegrini S., Civenni G., Zagalak J. A., Marchand J. R., Menzi M., Towbin H., Scheuermann J., Neri D., Caflisch A., Catapano C. V., Ciaudo C., Hall J.
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients
Gentile M., Shanafelt T. D., Rossi D., Laurenti L., Mauro F. R., Molica S., Cutrona G., Uccello G., Campanelli M., Vigna E., Tripepi G., Chaffee K. G., Parikh S. A., Bossio S., Recchia A. G., Innocenti I., Pasquale R., Neri A., Ferrarini M., Gaidano G., Foa R., Morabito F.
Targeting transcriptional co-activators in advanced prostate cancer
Groner A. C., Brown M., Theurillat J. P.
The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment
Albino D., Civenni G., Rossi S., Mitra A., Catapano C. V., Carbone G. M.
The ETS factor ESE3/EHF represses IL-6 preventing STAT3 activation and expansion of the prostate cancer stem-like compartment
Albino D., Civenni G., Rossi S., Mitra A., Catapano C. V., Carbone G. M.
Richter's syndrome: Novel and promising therapeutic alternatives
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes
Boi M., Todaro M., Vurchio V., Yang S. N., Moon J., Kwee I., Rinaldi A., Pan H., Crescenzo R., Cheng M., Cerchietti L., Elemento O., Riveiro M. E., Cvitkovic E., Bertoni F., Inghirami G., Airc xMille Consortium 'Genetics-Driven Targeted Management of Lymphoid Malignancies
Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia
Rossi D., Gerber B., Stussi G.
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Riveiro M. E., Astorgues-Xerri L., Vazquez R., Frapolli R., Kwee I., Rinaldi A., Odore E., Rezai K., Bekradda M., Inghirami G., D'Incalci M., Noel K., Cvitkovic E., Raymond E., Bertoni F.
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
Young E., Noerenberg D., Mansouri L., Ljungstrom V., Frick M., Sutton L. A., Blakemore S. J., Galan-Sousa J., Plevova K., Baliakas P., Rossi D., Clifford R., Roos-Weil D., Navrkalova V., Dorken B., Schmitt C. A., Smedby K. E., Juliusson G., Giacopelli B., Blachly J. S., Belessi C., Panagiotidis P., Chiorazzi N., Davi F., Langerak A. W., Oscier D., Schuh A., Gaidano G., Ghia P., Xu W., Fan L., Bernard O. A., Nguyen-Khac F., Rassenti L., Li J., Kipps T. J., Stamatopoulos K., Pospisilova S., Zenz T., Oakes C. C., Strefford J. C., Rosenquist R., Damm F.
Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay
Matic I., Revandkar A., Chen J., Bisio A., Dall'Acqua S., Cocetta V., Brun P., Mancino G., Milanese M., Mattei M., Montopoli M., Alimonti A.
Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment-naive chronic lymphocytic leukemia
Cavallini C., Visco C., Putta S., Rossi D., Mimiola E., Purvis N., Lovato O., Perbellini O., Falisi E., Facco M., Trentin L., Romanelli M. G., Semenzato G., Ambrosetti A., Gaidano G., Pizzolo G., Cesano A., Scupoli M. T.
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Vazquez R., Riveiro M. E., Astorgues-Xerri L., Odore E., Rezai K., Erba E., Panini N., Rinaldi A., Kwee I., Beltrame L., Bekradda M., Cvitkovic E., Bertoni F., Frapolli R., D'Incalci M.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence
Revandkar A., Perciato M. L., Toso A., Alajati A., Chen J., Gerber H., Dimitrov M., Rinaldi A., Delaleu N., Pasquini E., D'Antuono R., Pinton S., Losa M., Gnetti L., Arribas A., Fraering P., Bertoni F., Nepveu A., Alimonti A.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence
Revandkar A., Perciato M. L., Toso A., Alajati A., Chen J., Gerber H., Dimitrov M., Rinaldi A., Delaleu N., Pasquini E., D'Antuono R., Pinton S., Losa M., Gnetti L., Arribas A., Fraering P., Bertoni F., Nepveu A., Alimonti A.
Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence
Revandkar A., Perciato M. L., Toso A., Alajati A., Chen J., Gerber H., Dimitrov M., Rinaldi A., Delaleu N., Pasquini E., D'Antuono R., Pinton S., Losa M., Gnetti L., Arribas A., Fraering P., Bertoni F., Nepveu A., Alimonti A.
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation
Restelli V., Vagni M., Arribas A. J., Bertoni F., Damia G., Carrassa L.
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Rossi D., Diop F., Spaccarotella E., Monti S., Zanni M., Rasi S., Deambrogi C., Spina V., Bruscaggin A., Favini C., Serra R., Ramponi A., Boldorini R., Foa R., Gaidano G.
Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer
Calcinotto A., Alimonti A.
Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer
Calcinotto A., Alimonti A.
Aging tumour cells to cure cancer: "pro-senescence" therapy for cancer
Calcinotto A., Alimonti A.
Dnmt3a restrains mast cell inflammatory responses
Leoni C., Montagner S., Rinaldi A., Bertoni F., Polletti S., Balestrieri C., Monticelli S.
Methylation patterns in marginal zone lymphoma
Arribas A. J., Bertoni F.
Molecular pathogenesis of splenic and nodal marginal zone lymphoma
Spina V., Rossi D.
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia
Fabbri G., Holmes A. B., Viganotti M., Scuoppo C., Belver L., Herranz D., Yan X. J., Kieso Y., Rossi D., Gaidano G., Chiorazzi N., Ferrando A. A., Dalla-Favera R.
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors
Stathis A., Hess D., von Moos R., Homicsko K., Griguolo G., Joerger M., Mark M., Ackermann C. J., Allegrini S., Catapano C. V., Xyrafas A., Enoiu M., Berardi S., Gargiulo P., Sessa C., Swiss Group for Clinical Cancer Research
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components
Pozzo F., Bittolo T., Vendramini E., Bomben R., Bulian P., Rossi F. M., Zucchetto A., Tissino E., Degan M., D'Arena G., Di Raimondo F., Zaja F., Pozzato G., Rossi D., Gaidano G., Del Poeta G., Gattei V., Dal Bo M.
Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia
Bittolo T., Pozzo F., Bomben R., D'Agaro T., Bravin V., Bulian P., Rossi F. M., Zucchetto A., Degan M., Macor P., D'Arena G., Chiarenza A., Zaja F., Pozzato G., Di Raimondo F., Rossi D., Gaidano G., Del Poeta G., Gattei V., Dal Bo M.
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers
Pisignano G., Napoli S., Magistri M., Mapelli S. N., Pastori C., Di Marco S., Civenni G., Albino D., Enriquez C., Allegrini S., Mitra A., D'Ambrosio G., Mello-Grand M., Chiorino G., Garcia-Escudero R., Varani G., Carbone G. M., Catapano C. V.
A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers
Pisignano G., Napoli S., Magistri M., Mapelli S. N., Pastori C., Di Marco S., Civenni G., Albino D., Enriquez C., Allegrini S., Mitra A., D'Ambrosio G., Mello-Grand M., Chiorino G., Garcia-Escudero R., Varani G., Carbone G. M., Catapano C. V.
Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
Genini D., Brambilla L., Laurini E., Merulla J., Civenni G., Pandit S., D'Antuono R., Perez L., Levy D. E., Pricl S., Carbone G. M., Catapano C. V.
Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
Genini D., Brambilla L., Laurini E., Merulla J., Civenni G., Pandit S., D'Antuono R., Perez L., Levy D. E., Pricl S., Carbone G. M., Catapano C. V.
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide
Maffei R., Fiorcari S., Martinelli S., Benatti S., Bulgarelli J., Rizzotto L., Debbia G., Santachiara R., Rigolin G. M., Forconi F., Rossi D., Laurenti L., Palumbo G. A., Vallisa D., Cuneo A., Gaidano G., Luppi M., Marasca R.
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
Bernasconi E., Gaudio E., Lejeune P., Tarantelli C., Cascione L., Kwee I., Spriano F., Rinaldi A., Mensah A. A., Chung E., Stathis A., Siegel S., Schmees N., Ocker M., Zucca E., Haendler B., Bertoni F.
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Zabala-Letona A., Arruabarrena-Aristorena A., Martin-Martin N., Fernandez-Ruiz S., Sutherland J. D., Clasquin M., Tomas-Cortazar J., Jimenez J., Torres I., Quang P., Ximenez-Embun P., Bago R., Ugalde-Olano A., Loizaga-Iriarte A., Lacasa-Viscasillas I., Unda M., Torrano V., Cabrera D., van Liempd S. M., Cendon Y., Castro E., Murray S., Revandkar A., Alimonti A., Zhang Y., Barnett A., Lein G., Pirman D., Cortazar A. R., Arreal L., Prudkin L., Astobiza I., Valcarcel-Jimenez L., Zuniga-Garcia P., Fernandez-Dominguez I., Piva M., Caro-Maldonado A., Sanchez-Mosquera P., Castillo-Martin M., Serra V., Beraza N., Gentilella A., Thomas G., Azkargorta M., Elortza F., Farras R., Olmos D., Efeyan A., Anguita J., Munoz J., Falcon-Perez J. M., Barrio R., Macarulla T., Mato J. M., Martinez-Chantar M. L., Cordon-Cardo C., Aransay A. M., Marks K., Baselga J., Tabernero J., Nuciforo P., Manning B. D., Marjon K., Carracedo A.
NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types
D'Agaro T., Bittolo T., Bravin V., Dal Bo M., Pozzo F., Bulian P., Rossi F. M., Zucchetto A., Degan M., D'Arena G., Chiarenza A., Zaja F., Pozzato G., Di Raimondo F., Rossi D., Gaidano G., Del Poeta G., Gattei V., Bomben R.
Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study
Cascione L., Rinaldi A., Chiappella A., Kwee I., Ciccone G., Altenbuchinger M., Kohler C., Vitolo U., Inghirami G., Bertoni F.
Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia
Bulian P., Bomben R., Bo M. D., Zucchetto A., Rossi F. M., Degan M., Pozzo F., Bittolo T., Bravin V., D'Agaro T., Cerri M., Chiarenza A., Chaffee K. G., Condoluci A., D'Arena G., Spina M., Zaja F., Pozzato G., Di Raimondo F., Rossi D., Poeta G. D., Gaidano G., Shanafelt T. D., Gattei V.
PCSF: An R-package for network-based interpretation of high-throughput data
Akhmedov M., Kedaigle A., Chong R. E., Montemanni R., Bertoni F., Fraenkel E., Kwee I.
Natural antisense transcripts drive a regulatory cascade controlling c-MYC transcription
Napoli S., Piccinelli V., Mapelli S. N., Pisignano G., Catapano C. V.
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Janouskova H., El Tekle G., Bellini E., Udeshi N. D., Rinaldi A., Ulbricht A., Bernasocchi T., Civenni G., Losa M., Svinkina T., Bielski C. M., Kryukov G. V., Cascione L., Napoli S., Enchev R. I., Mutch D. G., Carney M. E., Berchuck A., Winterhoff B. J. N., Broaddus R. R., Schraml P., Moch H., Bertoni F., Catapano C. V., Peter M., Carr S. A., Garraway L. A., Wild P. J., Theurillat J. P.
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Janouskova H., El Tekle G., Bellini E., Udeshi N. D., Rinaldi A., Ulbricht A., Bernasocchi T., Civenni G., Losa M., Svinkina T., Bielski C. M., Kryukov G. V., Cascione L., Napoli S., Enchev R. I., Mutch D. G., Carney M. E., Berchuck A., Winterhoff B. J. N., Broaddus R. R., Schraml P., Moch H., Bertoni F., Catapano C. V., Peter M., Carr S. A., Garraway L. A., Wild P. J., Theurillat J. P.
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors
Janouskova H., El Tekle G., Bellini E., Udeshi N. D., Rinaldi A., Ulbricht A., Bernasocchi T., Civenni G., Losa M., Svinkina T., Bielski C. M., Kryukov G. V., Cascione L., Napoli S., Enchev R. I., Mutch D. G., Carney M. E., Berchuck A., Winterhoff B. J. N., Broaddus R. R., Schraml P., Moch H., Bertoni F., Catapano C. V., Peter M., Carr S. A., Garraway L. A., Wild P. J., Theurillat J. P.
Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
Rossi D., Condoluci A.
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile
Giudice I. D., Rigolin G. M., Raponi S., Cafforio L., Ilari C., Wang J., Bordyuh M., Piciocchi A., Marinelli M., Nanni M., Tavolaro S., Filetti M., Bardi A., Tammiso E., Volta E., Negrini M., Saccenti E., Mauro F. R., Rossi D., Gaidano G., Guarini A., Rabadan R., Cuneo A., Foa R.
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases
Gentile M., Shanafelt T. D., Mauro F. R., Laurenti L., Rossi D., Molica S., Vincelli I., Cutrona G., Uccello G., Pepe S., Vigna E., Tripepi G., Chaffee K. G., Parikh S. A., Bossio S., Recchia A. G., Innocenti I., Pasquale R., Neri A., Ferrarini M., Gaidano G., Foa R., Morabito F.
Treatment of Richter's Syndrome
Condoluci A., Rossi D.
Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia
Maffei R., Fiorcari S., Vaisitti T., Martinelli S., Benatti S., Debbia G., Rossi D., Zucchini P., Potenza L., Luppi M., Gaidano G., Deaglio S., Marasca R.
The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment
Gaidano G., Rossi D.
Drug-perturbation-based stratification of blood cancer
Dietrich S., Oles M., Lu J., Sellner L., Anders S., Velten B., Wu B., Hullein J., da Silva Liberio M., Walther T., Wagner L., Rabe S., Ghidelli-Disse S., Bantscheff M., Oles A. K., Slabicki M., Mock A., Oakes C. C., Wang S., Oppermann S., Lukas M., Kim V., Sill M., Benner A., Jauch A., Sutton L. A., Young E., Rosenquist R., Liu X., Jethwa A., Lee K. S., Lewis J., Putzker K., Lutz C., Rossi D., Mokhir A., Oellerich T., Zirlik K., Herling M., Nguyen-Khac F., Plass C., Andersson E., Mustjoki S., von Kalle C., Ho A. D., Hensel M., Durig J., Ringshausen I., Zapatka M., Huber W., Zenz T.
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas
Bandini C., Pupuleku A., Spaccarotella E., Pellegrino E., Wang R., Vitale N., Duval C., Cantarella D., Rinaldi A., Provero P., Di Cunto F., Medico E., Bertoni F., Inghirami G., Piva R.
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients
Raponi S., Del Giudice I., Marinelli M., Wang J., Cafforio L., Ilari C., Piciocchi A., Messina M., Bonina S., Tavolaro S., Bordyuh M., Mariglia P., Peragine N., Mauro F. R., Chiaretti S., Molica S., Gentile M., Visentin A., Trentin L., Rigolin G. M., Cuneo A., Diop F., Rossi D., Gaidano G., Guarini A., Rabadan R., Foa R.
Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines
Restelli V., Lupi M., Vagni M., Chila R., Bertoni F., Damia G., Carrassa L.
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
Malcikova J., Tausch E., Rossi D., Sutton L. A., Soussi T., Zenz T., Kater A. P., Niemann C. U., Gonzalez D., Davi F., Gonzalez Diaz M., Moreno C., Gaidano G., Stamatopoulos K., Rosenquist R., Stilgenbauer S., Ghia P., Pospisilova S., European Research Initiative on Chronic Lymphocytic Leukemia T. P. network
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
Gentile M., Shanafelt T. D., Reda G., Mauro F. R., Zirlik K., Ciolli S., Laurenti L., Del Principe M. I., Rossi D., Di Renzo N., Molica S., Angrilli F., Coscia M., Chiarenza A., Giordano A., Cutrona G., Chaffee K. G., Parikh S. A., Uccello G., Innocenti I., Tripepi G., D'Arrigo G., Vigna E., Recchia A. G., Herishanu Y., Shvidel L., Tadmor T., Cortelezzi A., Del Poeta G., Gaidano G., Di Raimondo F., Neri A., Ferrarini M., Foa R., Polliack A., Morabito F.
Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma
Spriano F., Chung E. Y., Panini N., Cascione L., Rinaldi A., Erba E., Stathis A., D'Incalci M., Bertoni F., Gatta R.
Recent advances in understanding the biology of marginal zone lymphoma
Bertoni F., Rossi D., Zucca E.
Recent advances in understanding the biology of marginal zone lymphoma
Bertoni F., Rossi D., Zucca E.
Biology and treatment of Richter syndrome
Rossi D., Spina V., Gaidano G.
Structural Biology of STAT3 and Its Implications for Anticancer Therapies Development
Sgrignani J., Garofalo M., Matkovic M., Merulla J., Catapano C. V., Cavalli A.
Pixantrone: novel mode of action and clinical readouts
Minotti G., Han H., Cattan V., Egorov A., Bertoni F.
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto A., Spataro C., Zagato E., Di Mitri D., Gil V., Crespo M., De Bernardis G., Losa M., Mirenda M., Pasquini E., Rinaldi A., Sumanasuriya S., Lambros M. B., Neeb A., Luciano R., Bravi C. A., Nava-Rodrigues D., Dolling D., Prayer-Galetti T., Ferreira A., Briganti A., Esposito A., Barry S., Yuan W., Sharp A., de Bono J., Alimonti A.
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto A., Spataro C., Zagato E., Di Mitri D., Gil V., Crespo M., De Bernardis G., Losa M., Mirenda M., Pasquini E., Rinaldi A., Sumanasuriya S., Lambros M. B., Neeb A., Luciano R., Bravi C. A., Nava-Rodrigues D., Dolling D., Prayer-Galetti T., Ferreira A., Briganti A., Esposito A., Barry S., Yuan W., Sharp A., de Bono J., Alimonti A.
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto A., Spataro C., Zagato E., Di Mitri D., Gil V., Crespo M., De Bernardis G., Losa M., Mirenda M., Pasquini E., Rinaldi A., Sumanasuriya S., Lambros M. B., Neeb A., Luciano R., Bravi C. A., Nava-Rodrigues D., Dolling D., Prayer-Galetti T., Ferreira A., Briganti A., Esposito A., Barry S., Yuan W., Sharp A., de Bono J., Alimonti A.
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
Morabito F., Shanafelt T. D., Gentile M., Reda G., Mauro F. R., Rossi D., Di Renzo N., Molica S., Angrilli F., Chiarenza A., Cutrona G., Chaffee K. G., Parikh S. A., Tripepi G., D'Arrigo G., Vigna E., Recchia A. G., Cortelezzi A., Gaidano G., Di Raimondo F., Fais F., Foa R., Neri A., Ferrarini M.
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma
Mensah A. A., Cascione L., Gaudio E., Tarantelli C., Bomben R., Bernasconi E., Zito D., Lampis A., Hahne J. C., Rinaldi A., Stathis A., Zucca E., Kwee I., Gattei V., Valeri N., Riveiro M. E., Bertoni F.
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., de Bono J., Carracedo A., Alimonti A.
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., de Bono J., Carracedo A., Alimonti A.
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., de Bono J., Carracedo A., Alimonti A.
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., de Bono J., Carracedo A., Alimonti A.
Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer
Chen J., Guccini I., Di Mitri D., Brina D., Revandkar A., Sarti M., Pasquini E., Alajati A., Pinton S., Losa M., Civenni G., Catapano C. V., Sgrignani J., Cavalli A., D'Antuono R., Asara J. M., Morandi A., Chiarugi P., Crotti S., Agostini M., Montopoli M., Masgras I., Rasola A., Garcia-Escudero R., Delaleu N., Rinaldi A., Bertoni F., de Bono J., Carracedo A., Alimonti A.
Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
Conconi A., Zucca E., Margiotta-Casaluci G., Darling K., Hasse B., Battegay M., Staehelin C., Novak U., Schmid P., Scherrer A., Dirnhofer S., Kwee I., Nassi L., Cavalli F., Gaidano G., Bertoni F., Bernasconi E., Swiss H. I. V. Cohort study
Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma
Condoluci A., Rossi D., Zucca E., Cavalli F.
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Nava Rodrigues D., Rescigno P., Liu D., Yuan W., Carreira S., Lambros M. B., Seed G., Mateo J., Riisnaes R., Mullane S., Margolis C., Miao D., Miranda S., Dolling D., Clarke M., Bertan C., Crespo M., Boysen G., Ferreira A., Sharp A., Figueiredo I., Keliher D., Aldubayan S., Burke K. P., Sumanasuriya S., Fontes M. S., Bianchini D., Zafeiriou Z., Teixeira Mendes L. S., Mouw K., Schweizer M. T., Pritchard C. C., Salipante S., Taplin M. E., Beltran H., Rubin M. A., Cieslik M., Robinson D., Heath E., Schultz N., Armenia J., Abida W., Scher H., Lord C., D'Andrea A., Sawyers C. L., Chinnaiyan A. M., Alimonti A., Nelson P. S., Drake C. G., Van Allen E. M., de Bono J. S.
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia
Baliakas P., Moysiadis T., Hadzidimitriou A., Xochelli A., Jeromin S., Agathangelidis A., Mattsson M., Sutton L. A., Minga E., Scarfo L., Rossi D., Davis Z., Villamor N., Parker H., Kotaskova J., Stalika E., Plevova K., Mansouri L., Cortese D., Navarro A., Delgado J., Larrayoz M., Young E., Anagnostopoulos A., Smedby K. E., Juliusson G., Sheehy O., Catherwood M., Strefford J. C., Stavroyianni N., Belessi C., Pospisilova S., Oscier D., Gaidano G., Campo E., Haferlach C., Ghia P., Rosenquist R., Stamatopoulos K., European Research Initiative on C. L. L.
How phosphorylation influences E1 subunit pyruvate dehydrogenase: A computational study
Sgrignani J., Chen J., Alimonti A., Cavalli A.
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
Tarantelli C., Bernasconi E., Gaudio E., Cascione L., Restelli V., Arribas A. J., Spriano F., Rinaldi A., Mensah A. A., Kwee I., Ponzoni M. M. D., Zucca E., Carrassa L., Riveiro M. E., Rezai K., Stathis A., Cvitkovic E., Bertoni F.
Mutant p53 blocks SESN1/AMPK/PGC-1alpha/UCP2 axis increasing mitochondrial O2-. production in cancer cells
Cordani M., Butera G., Dando I., Torrens-Mas M., Butturini E., Pacchiana R., Oppici E., Cavallini C., Gasperini S., Tamassia N., Nadal-Serrano M., Coan M., Rossi D., Gaidano G., Caraglia M., Mariotto S., Spizzo R., Roca P., Oliver J., Scupoli M. T., Donadelli M.
cuRnet: an R package for graph traversing on GPU
Bonnici V., Busato F., Aldegheri S., Akhmedov M., Cascione L., Carmena A. A., Bertoni F., Bombieri N., Kwee I., Giugno R.
Correction to: cuRnet: an R package for graph traversing on GPU
Bonnici V., Busato F., Aldegheri S., Akhmedov M., Cascione L., Carmena A. A., Bertoni F., Bombieri N., Kwee I., Giugno R.
Foreword
Rossi D., Zucca E.
Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
Calcinotto A., Brevi A., Chesi M., Ferrarese R., Garcia Perez L., Grioni M., Kumar S., Garbitt V. M., Sharik M. E., Henderson K. J., Tonon G., Tomura M., Miwa Y., Esplugues E., Flavell R. A., Huber S., Canducci F., Rajkumar V. S., Bergsagel P. L., Bellone M.
Deciphering the complexity of human non-coding promoter-proximal transcriptome
Mapelli S. N., Napoli S., Pisignano G., Garcia-Escudero R., Carbone G. M., Catapano C. V.
Deciphering the complexity of human non-coding promoter-proximal transcriptome
Mapelli S. N., Napoli S., Pisignano G., Garcia-Escudero R., Carbone G. M., Catapano C. V.
In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas
Tarantelli C., Gaudio E., Cascione L., Stathis A., Zucca E., Bertoni F.
Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients
Scimeca M., Urbano N., Bonfiglio R., Mapelli S. N., Catapano C. V., Carbone G. M., Ciuffa S., Tavolozza M., Schillaci O., Mauriello A., Bonanno E.
Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients
Scimeca M., Urbano N., Bonfiglio R., Mapelli S. N., Catapano C. V., Carbone G. M., Ciuffa S., Tavolozza M., Schillaci O., Mauriello A., Bonanno E.
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto A., Kohli J., Zagato E., Pellegrini L., Demaria M., Alimonti A.
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto A., Kohli J., Zagato E., Pellegrini L., Demaria M., Alimonti A.
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto A., Kohli J., Zagato E., Pellegrini L., Demaria M., Alimonti A.
Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma
Gonzalez-Rincon J., Mendez M., Gomez S., Garcia J. F., Martin P., Bellas C., Pedrosa L., Rodriguez-Pinilla S. M., Camacho F. I., Quero C., Perez-Callejo D., Rueda A., Llanos M., Gomez-Codina J., Piris M. A., Montes-Moreno S., Barcena C., Rodriguez-Abreu D., Menarguez J., de la Cruz-Merino L., Monsalvo S., Parejo C., Royuela A., Kwee I., Cascione L., Arribas A., Bertoni F., Mollejo M., Provencio M., Sanchez-Beato M.
Erratum to "Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients"
Scimeca M., Urbano N., Bonfiglio R., Mapelli S. N., Catapano C. V., Carbone G. M., Ciuffa S., Tavolozza M., Schillaci O., Mauriello A., Bonanno E.
Erratum to "Prostate Osteoblast-Like Cells: A Reliable Prognostic Marker of Bone Metastasis in Prostate Cancer Patients"
Scimeca M., Urbano N., Bonfiglio R., Mapelli S. N., Catapano C. V., Carbone G. M., Ciuffa S., Tavolozza M., Schillaci O., Mauriello A., Bonanno E.
Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq
Giannuzzi D., Marconato L., Cascione L., Comazzi S., Elgendy R., Pegolo S., Cecchinato A., Bertoni F., Aresu L., Ferraresso S.
DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas
Restelli V., Lupi M., Chila R., Vagni M., Tarantelli C., Spriano F., Gaudio E., Bertoni F., Damia G., Carrassa L.
Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer
Civenni G., Bosotti R., Timpanaro A., Vazquez R., Merulla J., Pandit S., Rossi S., Albino D., Allegrini S., Mitra A., Mapelli S. N., Vierling L., Giurdanella M., Marchetti M., Paganoni A., Rinaldi A., Losa M., Mira-Cato E., D'Antuono R., Morone D., Rezai K., D'Ambrosio G., Ouafik L., Mackenzie S., Riveiro M. E., Cvitkovic E., Carbone G. M., Catapano C. V.
Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer
Civenni G., Bosotti R., Timpanaro A., Vazquez R., Merulla J., Pandit S., Rossi S., Albino D., Allegrini S., Mitra A., Mapelli S. N., Vierling L., Giurdanella M., Marchetti M., Paganoni A., Rinaldi A., Losa M., Mira-Cato E., D'Antuono R., Morone D., Rezai K., D'Ambrosio G., Ouafik L., Mackenzie S., Riveiro M. E., Cvitkovic E., Carbone G. M., Catapano C. V.
Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
Civenni G., Albino D., Shinde D., Vazquez R., Merulla J., Kokanovic A., Mapelli S. N., Carbone G. M., Catapano C. V.
Transcriptional Reprogramming and Novel Therapeutic Approaches for Targeting Prostate Cancer Stem Cells
Civenni G., Albino D., Shinde D., Vazquez R., Merulla J., Kokanovic A., Mapelli S. N., Carbone G. M., Catapano C. V.
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
Tarantelli C., Gaudio E., Hillmann P., Spriano F., Sartori G., Aresu L., Cascione L., Rageot D., Kwee I., Beaufils F., Zucca E., Stathis A., Wymann M. P., Cmiljanovic V., Fabbro D., Bertoni F.
Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer
Shinde D., Albino D., Zoma M., Mutti A., Mapelli S. N., Civenni G., Kokanovic A., Merulla J., Perez-Escuredo J., Costales P., Moris F., Catapano C. V., Carbone G. M.
Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer
Shinde D., Albino D., Zoma M., Mutti A., Mapelli S. N., Civenni G., Kokanovic A., Merulla J., Perez-Escuredo J., Costales P., Moris F., Catapano C. V., Carbone G. M.
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome
Vannata B., Conconi A., Winkler J., Cascione L., Margiotta Casaluci G., Nassi L., Moia R., Pirosa M. C., Moccia A. A., Stathis A., Rossi D., Gaidano G., Zucca E.
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines
Fallacara A. L., Passannanti R., Mori M., Iovenitti G., Musumeci F., Greco C., Crespan E., Kissova M., Maga G., Tarantelli C., Spriano F., Gaudio E., Bertoni F., Botta M., Schenone S.
Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
Vazquez R., Civenni G., Kokanovic A., Shinde D., Cantergiani J., Marchetti M., Zoppi G., Ruggeri B., Liu P. C. C., Carbone G. M., Catapano C. V.
Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
Vazquez R., Civenni G., Kokanovic A., Shinde D., Cantergiani J., Marchetti M., Zoppi G., Ruggeri B., Liu P. C. C., Carbone G. M., Catapano C. V.
The Prospect and Challenges to the Flow of Liquid Biopsy in Africa
Temilola D. O., Wium M., Coulidiati T. H., Adeola H. A., Carbone G. M., Catapano C. V., Zerbini L. F.
The Prospect and Challenges to the Flow of Liquid Biopsy in Africa
Temilola D. O., Wium M., Coulidiati T. H., Adeola H. A., Carbone G. M., Catapano C. V., Zerbini L. F.
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
Di Mitri D., Mirenda M., Vasilevska J., Calcinotto A., Delaleu N., Revandkar A., Gil V., Boysen G., Losa M., Mosole S., Pasquini E., D'Antuono R., Masetti M., Zagato E., Chiorino G., Ostano P., Rinaldi A., Gnetti L., Graupera M., Martins Figueiredo Fonseca A. R., Pereira Mestre R., Waugh D., Barry S., De Bono J., Alimonti A.
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
Di Mitri D., Mirenda M., Vasilevska J., Calcinotto A., Delaleu N., Revandkar A., Gil V., Boysen G., Losa M., Mosole S., Pasquini E., D'Antuono R., Masetti M., Zagato E., Chiorino G., Ostano P., Rinaldi A., Gnetti L., Graupera M., Martins Figueiredo Fonseca A. R., Pereira Mestre R., Waugh D., Barry S., De Bono J., Alimonti A.
Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
Di Mitri D., Mirenda M., Vasilevska J., Calcinotto A., Delaleu N., Revandkar A., Gil V., Boysen G., Losa M., Mosole S., Pasquini E., D'Antuono R., Masetti M., Zagato E., Chiorino G., Ostano P., Rinaldi A., Gnetti L., Graupera M., Martins Figueiredo Fonseca A. R., Pereira Mestre R., Waugh D., Barry S., De Bono J., Alimonti A.
Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer
Civenni G., Carbone G. M., Catapano C. V.
Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer
Civenni G., Carbone G. M., Catapano C. V.
Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3
Trovato R., Fiore A., Sartori S., Cane S., Giugno R., Cascione L., Paiella S., Salvia R., De Sanctis F., Poffe O., Anselmi C., Hofer F., Sartoris S., Piro G., Carbone C., Corbo V., Lawlor R., Solito S., Pinton L., Mandruzzato S., Bassi C., Scarpa A., Bronte V., Ugel S.
Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization
Cascione L., Giudice L., Ferraresso S., Marconato L., Giannuzzi D., Napoli S., Bertoni F., Giugno R., Aresu L.
Mitochondrial fission and stemness in prostate cancer
Civenni G., Carbone G. M., Catapano C. V.
Mitochondrial fission and stemness in prostate cancer
Civenni G., Carbone G. M., Catapano C. V.
Cellular Senescence: Defining a Path Forward
Gorgoulis V., Adams P. D., Alimonti A., Bennett D. C., Bischof O., Bishop C., Campisi J., Collado M., Evangelou K., Ferbeyre G., Gil J., Hara E., Krizhanovsky V., Jurk D., Maier A. B., Narita M., Niedernhofer L., Passos J. F., Robbins P. D., Schmitt C. A., Sedivy J., Vougas K., von Zglinicki T., Zhou D., Serrano M., Demaria M.
A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)
Mapelli S. N., Albino D., Mello-Grand M., Shinde D., Scimeca M., Bonfiglio R., Bonanno E., Chiorino G., Garcia-Escudero R., Catapano C. V., Carbone G. M.
A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)
Mapelli S. N., Albino D., Mello-Grand M., Shinde D., Scimeca M., Bonfiglio R., Bonanno E., Chiorino G., Garcia-Escudero R., Catapano C. V., Carbone G. M.
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression
Tissino E., Pozzo F., Benedetti D., Caldana C., Bittolo T., Rossi F. M., Bomben R., Nanni P., Chivilo H., Cattarossi I., Zaina E., Norris K., Polesel J., Gentile M., Tripepi G., Moia R., Santinelli E., Innocenti I., Olivieri J., D'Arena G., Laurenti L., Zaja F., Pozzato G., Chiarenza A., Di Raimondo F., Rossi D., Pepper C., Hartmann T. N., Gaidano G., Del Poeta G., Gattei V., Zucchetto A.
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
Raponi S., Ilari C., Della Starza I., Cappelli L. V., Cafforio L., Piciocchi A., Arena V., Mariglia P., Mauro F. R., Gentile M., Cutrona G., Moia R., Favini C., Morabito F., Rossi D., Gaidano G., Guarini A., Del Giudice I., Foa R.
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients
Lionetti M., Barbieri M., Favasuli V., Taiana E., Fabris S., Favoino C., Ciceri G., Matis S., Colombo M., Massara R., Reda G., Gentile M., Spina V., Rossi D., Baldini L., Gaidano G., Fais F., Ferrarini M., Morabito F., Cutrona G., Neri A.
De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders
Nabais Sa M. J., El Tekle G., de Brouwer A. P. M., Sawyer S. L., Del Gaudio D., Parker M. J., Kanani F., van den Boogaard M. H., van Gassen K., Van Allen M. I., Wierenga K., Purcarin G., Elias E. R., Begtrup A., Keller-Ramey J., Bernasocchi T., van de Wiel L., Gilissen C., Venselaar H., Pfundt R., Vissers Lelm, Theurillat J. P., de Vries B. B. A.
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Tarantelli C., Lange M., Gaudio E., Cascione L., Spriano F., Kwee I., Arribas A. J., Rinaldi A., Jourdan T., Berthold M., Sturz A., Sperl C., Margheriti F., Scalise L., Gritti G., Rossi D., Stathis A., Liu N., Zucca E., Politz O., Bertoni F.
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Tarantelli C., Lange M., Gaudio E., Cascione L., Spriano F., Kwee I., Arribas A. J., Rinaldi A., Jourdan T., Berthold M., Sturz A., Sperl C., Margheriti F., Scalise L., Gritti G., Rossi D., Stathis A., Liu N., Zucca E., Politz O., Bertoni F.
Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog
Giannuzzi D., Giudice L., Marconato L., Ferraresso S., Giugno R., Bertoni F., Aresu L.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati A., D'Ambrosio M., Troiani M., Mosole S., Pellegrini L., Chen J., Revandkar A., Bolis M., Theurillat J. P., Guccini I., Losa M., Calcinotto A., De Bernardis G., Pasquini E., D'Antuono R., Sharp A., Figueiredo I., Nava Rodrigues D., Welti J., Gil V., Yuan W., Vlajnic T., Bubendorf L., Chiorino G., Gnetti L., Torrano V., Carracedo A., Camplese L., Hirabayashi S., Canato E., Pasut G., Montopoli M., Ruschoff J. H., Wild P., Moch H., De Bono J., Alimonti A.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati A., D'Ambrosio M., Troiani M., Mosole S., Pellegrini L., Chen J., Revandkar A., Bolis M., Theurillat J. P., Guccini I., Losa M., Calcinotto A., De Bernardis G., Pasquini E., D'Antuono R., Sharp A., Figueiredo I., Nava Rodrigues D., Welti J., Gil V., Yuan W., Vlajnic T., Bubendorf L., Chiorino G., Gnetti L., Torrano V., Carracedo A., Camplese L., Hirabayashi S., Canato E., Pasut G., Montopoli M., Ruschoff J. H., Wild P., Moch H., De Bono J., Alimonti A.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati A., D'Ambrosio M., Troiani M., Mosole S., Pellegrini L., Chen J., Revandkar A., Bolis M., Theurillat J. P., Guccini I., Losa M., Calcinotto A., De Bernardis G., Pasquini E., D'Antuono R., Sharp A., Figueiredo I., Nava Rodrigues D., Welti J., Gil V., Yuan W., Vlajnic T., Bubendorf L., Chiorino G., Gnetti L., Torrano V., Carracedo A., Camplese L., Hirabayashi S., Canato E., Pasut G., Montopoli M., Ruschoff J. H., Wild P., Moch H., De Bono J., Alimonti A.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati A., D'Ambrosio M., Troiani M., Mosole S., Pellegrini L., Chen J., Revandkar A., Bolis M., Theurillat J. P., Guccini I., Losa M., Calcinotto A., De Bernardis G., Pasquini E., D'Antuono R., Sharp A., Figueiredo I., Nava Rodrigues D., Welti J., Gil V., Yuan W., Vlajnic T., Bubendorf L., Chiorino G., Gnetti L., Torrano V., Carracedo A., Camplese L., Hirabayashi S., Canato E., Pasut G., Montopoli M., Ruschoff J. H., Wild P., Moch H., De Bono J., Alimonti A.
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo
Alajati A., D'Ambrosio M., Troiani M., Mosole S., Pellegrini L., Chen J., Revandkar A., Bolis M., Theurillat J. P., Guccini I., Losa M., Calcinotto A., De Bernardis G., Pasquini E., D'Antuono R., Sharp A., Figueiredo I., Nava Rodrigues D., Welti J., Gil V., Yuan W., Vlajnic T., Bubendorf L., Chiorino G., Gnetti L., Torrano V., Carracedo A., Camplese L., Hirabayashi S., Canato E., Pasut G., Montopoli M., Ruschoff J. H., Wild P., Moch H., De Bono J., Alimonti A.
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
Condoluci A., Terzi di Bergamo L., Langerbeins P., Hoechstetter M. A., Herling C. D., De Paoli L., Delgado J., Rabe K. G., Gentile M., Doubek M., Mauro F. R., Chiodin G., Mattsson M., Bahlo J., Cutrona G., Kotaskova J., Deambrogi C., Smedby K. E., Spina V., Bruscaggin A., Wu W., Moia R., Bianchi E., Gerber B., Zucca E., Gillessen S., Ghielmini M., Cavalli F., Stussi G., Hess M. A., Baumann T. S., Neri A., Ferrarini M., Rosenquist R., Forconi F., Foa R., Pospisilova S., Morabito F., Stilgenbauer S., Dohner H., Parikh S. A., Wierda W. G., Montserrat E., Gaidano G., Hallek M., Rossi D.
Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
Sutton L. A., Ljungström V., Enjuanes A., Cortese D., Skaftason A., Tausch E., Stano Kozubik K., Nadeu F., Armand M., Malcikova J., Pandzic T., Forster J., Davis Z., Oscier D., Rossi D., Ghia P., Strefford J. C., Pospisilova S., Stilgenbauer S., Davi F., Campo E., Stamatopoulos K., Rosenquist R., On Behalf Of The European Research Initiative On Cll Eric
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
Gentile M., Morabito F., Del Poeta G., Mauro F. R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Recchia A. G., Varettoni M., Murru R., Chiarenza A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F. M., Zucchetto A., Fraticelli V., Vigna E., Botta C., Tripepi G., Arrigo G., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Rigolin G. M., Rossi D., Di Raimondo F., Gaidano G., Polliack A., Cuneo A., Foa R., Gattei V.
An overview on anti-tubulin agents for the treatment of lymphoma patients
Barreca M., Stathis A., Barraja P., Bertoni F.
Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo
Berk C., Civenni G., Wang Y., Steuer C., Catapano C. V., Hall J.
STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer
Oberhuber M., Pecoraro M., Rusz M., Oberhuber G., Wieselberg M., Haslinger P., Gurnhofer E., Schlederer M., Limberger T., Lagger S., Pencik J., Kodajova P., Hogler S., Stockmaier G., Grund-Groschke S., Aberger F., Bolis M., Theurillat J. P., Wiebringhaus R., Weiss T., Haitel A., Brehme M., Wadsak W., Griss J., Mohr T., Hofer A., Jager A., Pollheimer J., Egger G., Koellensperger G., Mann M., Hantusch B., Kenner L.
Exploring the Ubiquitin-Proteasome System (UPS) through PROTAC Technology
Cecchini C., Tardy S., Ceserani V., Theurillat J. P., Scapozza L.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532)
Montopoli M., Zumerle S., Vettor R., Rugge M., Zorzi M., Catapano C. V., Carbone G. M., Cavalli A., Pagano F., Ragazzi E., Prayer-Galetti T., Alimonti A.
Prostate carcinogenesis: inflammatory storms
de Bono J. S., Guo C., Gurel B., De Marzo A. M., Sfanos K. S., Mani R. S., Gil J., Drake C. G., Alimonti A.
In and out from senescence
Zumerle S., Alimonti A.
Reply to Aron P. Kater et al
Moia R., Gaidano G., Rossi D.
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
Scarfo L., Chatzikonstantinou T., Rigolin G. M., Quaresmini G., Motta M., Vitale C., Garcia-Marco J. A., Hernandez-Rivas J. A., Miras F., Baile M., Marquet J., Niemann C. U., Reda G., Munir T., Gimeno E., Marchetti M., Quaglia F. M., Varettoni M., Delgado J., Iyengar S., Janssens A., Marasca R., Ferrari A., Cuellar-Garcia C., Itchaki G., Spacek M., De Paoli L., Laurenti L., Levin M. D., Lista E., Mauro F. R., Simkovic M., Van Der Spek E., Vandenberghe E., Trentin L., Wasik-Szczepanek E., Ruchlemer R., Bron D., De Paolis M. R., Del Poeta G., Farina L., Foglietta M., Gentile M., Herishanu Y., Herold T., Jaksic O., Kater A. P., Kersting S., Malerba L., Orsucci L., Popov V. M., Sportoletti P., Yassin M., Pocali B., Barna G., Chiarenza A., Dos Santos G., Nikitin E., Andres M., Dimou M., Doubek M., Enrico A., Hakobyan Y., Kalashnikova O., Ortiz Pareja M., Papaioannou M., Rossi D., Shah N., Shrestha A., Stanca O., Stavroyianni N., Strugov V., Tam C., Zdrenghea M., Coscia M., Stamatopoulos K., Rossi G., Rambaldi A., Montserrat E., Foa R., Cuneo A., Ghia P.
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
Priebe V., Sartori G., Napoli S., Chung E. Y. L., Cascione L., Kwee I., Arribas A. J., Mensah A. A., Rinaldi A., Ponzoni M., Zucca E., Rossi D., Efremov D., Lenz G., Thome M., Bertoni F.
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
Priebe V., Sartori G., Napoli S., Chung E. Y. L., Cascione L., Kwee I., Arribas A. J., Mensah A. A., Rinaldi A., Ponzoni M., Zucca E., Rossi D., Efremov D., Lenz G., Thome M., Bertoni F.
Targeting BET bromodomain proteins in cancer: The example of lymphomas
Spriano F., Stathis A., Bertoni F.
P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors
Romagnani A., Rottoli E., Mazza E. M. C., Rezzonico-Jost T., De Ponte Conti B., Proietti M., Perotti M., Civanelli E., Perruzza L., Catapano A. L., Baragetti A., Tenedini E., Tagliafico E., Falzoni S., Di Virgilio F., Norata G. D., Bicciato S., Grassi F.
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
Benz R., Arn K., Andres M., Pabst T., Baumann M., Novak U., Hitz F., Hess U., Zenhaeusern R., Chalandon Y., Mey U., Blum S., Rauch D., O'Meara Stern A., Cantoni N., Bargetzi M., Bianchi-Papina E., Rossi D., Passweg J., Lohri A., Berardi S., Li Q., Feller A., Stussi G.
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
Rossi D., Shadman M., Condoluci A., Brown J. R., Byrd J. C., Gaidano G., Hallek M., Hillmen P., Mato A., Montserrat E., Ghia P.
Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
Kessler C., Stricker H., Demundo D., Elzi L., Monotti R., Bianchi G., Llamas M., Spinedi L., Rossi D., Chiesa A. F., Pagnamenta A., Conti M., Casso G., Stoira E., Valenti E., Colucci G., Stussi G., Gerber B., Previsdomini M.
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734
Spriano F., Gaudio E., Cascione L., Tarantelli C., Melle F., Motta G., Priebe V., Rinaldi A., Golino G., Mensah A. A., Aresu L., Zucca E., Pileri S., Witcher M., Brown B., Wahlestedt C., Giles F., Stathis A., Bertoni F.
Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences
Carrassa L., Colombo I., Damia G., Bertoni F.
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
Agathangelidis A., Chatzidimitriou A., Gemenetzi K., Giudicelli V., Karypidou M., Plevova K., Davis Z., Yan X. J., Jeromin S., Schneider C., Pedersen L. B., Tschumper R. C., Sutton L. A., Baliakas P., Scarfo L., van Gastel E. J., Armand M., Tausch E., Biderman B., Baer C., Bagnara D., Navarro A., Langlois de Septenville A., Guido V., Mitterbauer-Hohendanner G., Dimovski A., Brieghel C., Lawless S., Meggendorfer M., Brazdilova K., Ritgen M., Facco M., Tresoldi C., Visentin A., Patriarca A., Catherwood M., Bonello L., Sudarikov A., Vanura K., Roumelioti M., Skuhrova Francova H., Moysiadis T., Veronese S., Giannopoulos K., Mansouri L., Karan-Djurasevic T., Sandaltzopoulos R., Bodor C., Fais F., Kater A., Panovska I., Rossi D., Alshemmari S., Panagiotidis P., Costeas P., Espinet B., Antic D., Foroni L., Montillo M., Trentin L., Stavroyianni N., Gaidano G., Francia di Celle P., Niemann C., Campo E., Anagnostopoulos A., Pott C., Fischer K., Hallek M., Oscier D., Stilgenbauer S., Haferlach C., Jelinek D., Chiorazzi N., Pospisilova S., Lefranc M. P., Kossida S., Langerak A. W., Belessi C., Davi F., Rosenquist R., Ghia P., Stamatopoulos K.
SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia
Condoluci A., Rossi D.
Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176
Mapelli S. N., Albino D., Mello-Grand M., Shinde D., Scimeca M., Bonfiglio R., Bonanno E., Chiorino G., Garcia-Escudero R., Catapano C. V., Carbone G. M.
Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176
Mapelli S. N., Albino D., Mello-Grand M., Shinde D., Scimeca M., Bonfiglio R., Bonanno E., Chiorino G., Garcia-Escudero R., Catapano C. V., Carbone G. M.
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Gaudio E., Tarantelli C., Spriano F., Guidetti F., Sartori G., Bordone R., Arribas A. J., Cascione L., Bigioni M., Merlino G., Fiascarelli A., Bressan A., Adjeiwaa Mensah A., Golino G., Lucchini R., Bernasconi E., Rossi D., Zucca E., Stussi G., Stathis A., Boyd R. S., Dusek R. L., Bisht A., Attanasio N., Rohlff C., Pellacani A., Binaschi M., Bertoni F.
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Gaudio E., Tarantelli C., Spriano F., Guidetti F., Sartori G., Bordone R., Arribas A. J., Cascione L., Bigioni M., Merlino G., Fiascarelli A., Bressan A., Adjeiwaa Mensah A., Golino G., Lucchini R., Bernasconi E., Rossi D., Zucca E., Stussi G., Stathis A., Boyd R. S., Dusek R. L., Bisht A., Attanasio N., Rohlff C., Pellacani A., Binaschi M., Bertoni F.
Novel sigma1 antagonists designed for tumor therapy: Structure - activity relationships of aminoethyl substituted cyclohexanes
Kopp N., Holtschulte C., Borgel F., Lehmkuhl K., Friedland K., Civenni G., Laurini E., Catapano C. V., Pricl S., Humpf H. U., Schepmann D., Wunsch B.
Genetic and hormonal influence on SARS-CoV-2-infection susceptibility: Re: The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality
Montopoli M., Zumerle S., Rugge M., Alimonti A.
Reply to the Letter to the Editor "Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients" by N. Bennani and I. M. Bennani-Baiti
Zumerle S., Montopoli M., Rugge M., Alimonti A.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases
Morabito F., Tripepi G., Del Poeta G., Mauro F. R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Bossio S., Varettoni M., Murru R., Chiarenza A., Visentin A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F. M., Zucchetto A., Al-Janazreh H., Vigna E., Martino E. A., Mendicino F., Cassin R., D'Arrigo G., Galimberti S., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Neri A., Fronza G., Monti P., Menichini P., Cutrona G., Jaksic O., Rossi D., Di Raimondo F., Cuneo A., Gaidano G., Polliack A., Trentin L., Foa R., Ferrarini M., Gattei V., Gentile M.
Genomic Instability and Clonal Evolution in Chronic Lymphocytic Leukemia: Clinical Relevance
Condoluci A., Rossi D.
Data describing the effects of potassium channels modulators on outward currents measured in human lymphoma cell lines
Montalbano A., Sala C., Abrardo C., Murciano N., Jahanfar F., D'Amico M., Bertoni F., Becchetti A., Arcangeli A.
Loss and revival of androgen receptor signaling in advanced prostate cancer
Formaggio N., Rubin M. A., Theurillat J. P.
Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors
Unzue A., Jessen-Trefzer C., Spiliotopoulos D., Gaudio E., Tarantelli C., Dong J., Zhao H., Pachmayr J., Zahler S., Bernasconi E., Sartori G., Cascione L., Bertoni F., Sledz P., Caflisch A., Nevado C.
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Albino D., Falcione M., Uboldi V., Temilola D. O., Sandrini G., Merulla J., Civenni G., Kokanovic A., Sturchler A., Shinde D., Garofalo M., Mestre R. P., Constancio V., Wium M., Burrello J., Baranzini N., Grimaldi A., Theurillat J. P., Bossi D., Barile L., Henrique R. M., Jeronimo C., Zerbini L. F., Catapano C. V., Carbone G. M.
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Albino D., Falcione M., Uboldi V., Temilola D. O., Sandrini G., Merulla J., Civenni G., Kokanovic A., Sturchler A., Shinde D., Garofalo M., Mestre R. P., Constancio V., Wium M., Burrello J., Baranzini N., Grimaldi A., Theurillat J. P., Bossi D., Barile L., Henrique R. M., Jeronimo C., Zerbini L. F., Catapano C. V., Carbone G. M.
Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Albino D., Falcione M., Uboldi V., Temilola D. O., Sandrini G., Merulla J., Civenni G., Kokanovic A., Sturchler A., Shinde D., Garofalo M., Mestre R. P., Constancio V., Wium M., Burrello J., Baranzini N., Grimaldi A., Theurillat J. P., Bossi D., Barile L., Henrique R. M., Jeronimo C., Zerbini L. F., Catapano C. V., Carbone G. M.
Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients who underwent antiestrogenic therapy
Montopoli M., Zorzi M., Cocetta V., Prayer-Galetti T., Guzzinati S., Bovo E., Rugge M., Calcinotto A.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Bernasocchi T., El Tekle G., Bolis M., Mutti A., Vallerga A., Brandt L. P., Spriano F., Svinkina T., Zoma M., Ceserani V., Rinaldi A., Janouskova H., Bossi D., Cavalli M., Mosole S., Geiger R., Dong Z., Yang C. G., Albino D., Rinaldi A., Schraml P., Linder S., Carbone G. M., Alimonti A., Bertoni F., Moch H., Carr S. A., Zwart W., Kruithof-de Julio M., Rubin M. A., Udeshi N. D., Theurillat J. P.
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1
Kohlhaas V., Blakemore S. J., Al-Maarri M., Nickel N., Pal M., Roth A., Hovelmeyer N., Schafer S. C., Knittel G., Lohneis P., Nikolic M., Wiederstein J. L., Franitza M., Georgomonolis T., Reinart N., Herling M., Herling C., Hartmann E. M., Rosenwald A., Klapper W., Buttner R., Moia R., Rossi D., Boldorini R., Gaidano G., Frenzel L. P., Reinhardt H. C., Bruning J. C., Hallek M., Kruger M., Peifer M., Pallasch C. P., Wunderlich F. T.
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients
Baumann T., Moia R., Gaidano G., Delgado J., Condoluci A., Villamor N., Payedimarri A. B., Costa D., Patriarca A., Jimenez-Vicente C., Rossi D., Montserrat E.
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa M., Guffanti F., Bertoni F., Colombo I., Damia G.
Richter Syndrome
Condoluci A., Rossi D.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
Morabito F., Tripepi G., Del Poeta G., Mauro F. R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Varettoni M., Murru R., Chiarenza A., Visentin A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F. M., Zucchetto A., Vigna E., Martino E. A., Mendicino F., Botta C., Caracciolo D., Cassin R., D'Arrigo G., Galimberti S., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Neri A., Fronza G., Cutrona G., Rossi D., Di Raimondo F., Cuneo A., Gaidano G., Polliack A., Trentin L., Foa R., Ferrarini M., Gattei V., Gentile M.
Patient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna S., La Manna F., Benjak A., Kiener M., De Menna M., Zoni E., Grosjean J., Klima I., Garofoli A., Bolis M., Vallerga A., Theurillat J. P., De Filippo M. R., Genitsch V., Keller D., Booij T. H., Stirnimann C. U., Eng K., Sboner A., Ng C. K. Y., Piscuoglio S., Gray P. C., Spahn M., Rubin M. A., Thalmann G. N., Kruithof-de Julio M.
CD38 in Advanced Prostate Cancers
Guo C., Crespo M., Gurel B., Dolling D., Rekowski J., Sharp A., Petremolo A., Sumanasuriya S., Rodrigues D. N., Ferreira A., Pereira R., Figueiredo I., Mehra N., Lambros M. B. K., Neeb A., Gil V., Seed G., Terstappen L., Alimonti A., Drake C. G., Yuan W., de Bono J. S., International S. U. C. P. C. F. Prostate Cancer Dream Team
Role of myeloid-derived suppressor cells in hormone-dependent cancers
Mukherjee S., Elia A. R., Calcinotto A.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials
Morabito F., Tripepi G., Del Poeta G., Mauro F. R., Reda G., Sportoletti P., Laurenti L., Coscia M., Herishanu Y., Bossio S., Varettoni M., Murru R., Chiarenza A., Visentin A., Condoluci A., Moia R., Pietrasanta D., Loseto G., Consoli U., Scortechini I., Rossi F. M., Zucchetto A., Al-Janazreh H., Vigna E., Martino E. A., Cassin R., D'Arrigo G., Galimberti S., Rago A., Angeletti I., Biagi A., Del Giudice I., Bomben R., Neri A., Fronza G., Monti P., Menichini P., Olivieri J., Cutrona G., Rossi D., Cuneo A., Di Raimondo F., Gaidano G., Polliack A., Trentin L., Foa R., Ferrarini M., Gattei V., Gentile M.
RNAdetector: a free user-friendly stand-alone and cloud-based system for RNA-Seq data analysis
La Ferlita A., Alaimo S., Di Bella S., Martorana E., Laliotis G. I., Bertoni F., Cascione L., Tsichlis P. N., Ferro A., Bosotti R., Pulvirenti A.
EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
Zoma M., Curti L., Shinde D., Albino D., Mitra A., Sgrignani J., Mapelli S. N., Sandrini G., Civenni G., Merulla J., Chiorino G., Kunderfranco P., Cacciatore A., Kokanovic A., Rinaldi A., Cavalli A., Catapano C. V., Carbone G. M.
EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
Zoma M., Curti L., Shinde D., Albino D., Mitra A., Sgrignani J., Mapelli S. N., Sandrini G., Civenni G., Merulla J., Chiorino G., Kunderfranco P., Cacciatore A., Kokanovic A., Rinaldi A., Cavalli A., Catapano C. V., Carbone G. M.
ApoE-TREM2 axis induces pathogenic senescent-like myeloid cells in prostate cancer
Calcinotto A., Bancaro N., Troiani M., Arzola R., Elia A. R., Attanasio G., Calì B., Crespo M., Gurel B., Pereira R.
Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin
Roggero E., Zucca E., Mainetti C., Bertoni F., Valsangiacomo C., Pedrinis E., Borisch B., Piffaretti J. C., Cavalli F., Isaacson P. G.
Bayesian network data imputation with application to survival tree analysis
Rancoita P. M. , Zaffalon M., Zucca E., Bertoni F., de Campos C. P.
Tumor-secreted exosomal miR-424: impact on prostate tumorigenesis in mouse models and patients
Albino D., Uboldi V., Sturchler A., Falcione M., Shinde D., Merulla J., Cacciatore A., Civenni G., Garofalo M., Grimaldi A., Constâncio V., Henrique R. M., Jeronimo C., Catapano C. V., Carbone G. M.
Tumor-secreted exosomal miR-424: impact on prostate tumorigenesis in mouse models and patients
Albino D., Uboldi V., Sturchler A., Falcione M., Shinde D., Merulla J., Cacciatore A., Civenni G., Garofalo M., Grimaldi A., Constâncio V., Henrique R. M., Jeronimo C., Catapano C. V., Carbone G. M.
Epigenetic reprogramming and mitochondrial dynamics drive self-renewal and tumorigenic capability of prostate cancer stem cells: new prospects for treatment of prostate cancer
Civenni G., Vasquez R., Merulla J., Pandit S., Kokanovic A., Timpanaro A., Vierling L., Giurdanella M., Sorrenti E., Migheli R., Shinde D., Albino D., Carbone G. M., Catapano C.
Epigenetic reprogramming and mitochondrial dynamics drive self-renewal and tumorigenic capability of prostate cancer stem cells: new prospects for treatment of prostate cancer
Civenni G., Vasquez R., Merulla J., Pandit S., Kokanovic A., Timpanaro A., Vierling L., Giurdanella M., Sorrenti E., Migheli R., Shinde D., Albino D., Carbone G. M., Catapano C.

The Institute

Research

Facilities Facilities

Education

News and events News and events

Publications

Stay in touch

More about USI

IOR is member of